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SUMMARY 
 
Summary 
 
Echinococcus granulosus and Echinococcus multilocularis are the two 
tapeworm species responsible for the majority of human echinococcosis 
cases. Infection of this zoonosis can be acquired all over the world by 
accidental ingestion of eggs. The prevalence of echinococcosis is highest in 
areas with extensive animal husbandry.  
 
Most diagnostic tests for the detection of antibodies against echinococcosis in 
humans are based on crude or partly purified native antigen extracts. The 
production of standardized diagnostic-grade native antigen is not possible. 
Native antigen suffers from batch-to-batch variation depending on purity, 
origin and developmental stage of the parasite material. In addition, native 
antigen is limited in availability.  
 
Substantial progress in the development of standardized reagents has been 
achieved by the production of recombinant antigens. Consequent further 
development of antigens might lead to the production of synthetic antigen.  
 
This PhD thesis investigated the applicability of synthetic peptides ranging 
from 24 to 47 amino acids in length for the use as synthetic antigens in 
serological diagnosis of cystic and alveolar echinococcosis. A bioinformatic 
selection procedure was established for identification of potentially antigenic 
protein sequences. From each of these parent proteins one or several 
peptides were selected for chemical synthesis. Peptides were designed from 
predicted domains of alpha-helical coiled-coils and intrinsically unstructured 
regions. These two motifs are capable of adopting their natural conformation 
even if synthesized as isolated fragments. The diagnostic performance of a 
synthetic antigen depends on its ability to fold into its native structure and thus 
be recognized by antibodies that had been naturally induced in the course of 
an infection.  
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Peptide candidates were designed from different sets of parent proteins which 
had been selected by three different approaches: i) a genomics approach, ii) a 
proteomics approach, and iii) a transcriptomics approach.  
 
These three approaches identified 6 promising peptide candidates. The 
synthetic peptide performing best obtained a sensitivity of 74% for the 
detection of CE infection and 43% for the detection of AE infection in adult 
patients. Specificity was 94%. All identified peptides, apart from one 
candidate, were not able to discriminate between CE and AE infection.  
 
The major drawback of using peptides for serodiagnosis was their reduced 
sensitivity compared to EgHF, the native antigen used in routine diagnostics. 
Our results indicated that test sensitivity could be increased by combination of 
several peptides into a pool of synthetic antigen. This strategy can solve the 
problem of decreased sensitivity in future assay development.  
 
The most promising candidate, peptide longD8-9, was investigated as 
potential marker for serological follow-up of treatment success in young 
patients. This represents a novelty, as synthetic peptides have not yet been 
tested as marker for serological follow-up of CE patients.  
 
The performance of longD8-9-ELISA compared well to that of EgHF-ELISA, 
but it was superior in that within three years after treatment, more cured CE 
patients reached seronegativity in peptide ELISA compared to EgHF ELISA. 
Non-cured CE patients produced highly positive test results until the end of 
the follow-up period.  
 
This thesis provides proof-of-principle for the discovery of diagnostically 
relevant peptides by bioinformatic selection complemented with screening on 
a high-throughput microarray platform. It also showed the value of synthetic 
peptides as potential markers not only in primary diagnosis, but also in 
monitoring of treatment outcome in follow-up patients. 
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Abbreviations 
 
ABZ    Albendazole 
AE    Alveolar echinococcosis caused by E. multilocularis 
AHX   Aminohexanoic acid 
CC   Alpha-helical coiled-coil 
CCE    Cured cystic echinococcosis 
CE   Cystic echinococcosis caused by E. granulosus 
cMDH   Cytosolic malate dehydrogenase 
CT    Computed tomography 
EgHF   E. granulosus hydatid cyst fluid 
ELISA   enzyme-linked-immunosorbent assay 
EmVF   E. multilocularis vesicle fluid 
EST   Expressed sequence tag 
FI   Fluorescence intensity 
GPI    Glycosylphosphatidylinositol 
IB    Immunoblotting 
IFAT    Indirect fluoresence antibody test 
IHA   Indirect hem agglutination 
IUR   Intrinsically unstructured region 
LSP   Long synthetic peptide 
MRI   Magnetic resonance imaging 
MS   Mass spectrometry 
NCCE   Non-cured cystic echinococcosis 
PAIR   Puncture, aspiration, injection, re-aspiration 
PEG   Polyethylene glycol 
TM   Transmembrane domain 
US   Ultrasound imaging 
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General introduction 
Echinococcosis in humans 
Human echinococcosis is a zoonosis caused by tapeworms of the genus 
Echinococcus. There are several species infecting man, E. granulosus and E. 
multilocularis being the two most important. The disease in humans is caused 
by the growth of the metacestode larva in the liver, lungs or any other organ. 
Infection with E. granulosus causes cystic echinococcosis (CE) which is 
characterized by unilocular cysts, while the infection with E. multilocularis 
causing alveolar echinococcosis (AE) is characterized by the growth of 
infiltrating, tumor-like metacestode tissue scattered with multiple vesicles. 
Figure 1 depicts the life cycle of both tapeworm species and illustrates the 
appearance of the metacestode larvae (from Wen et al. [1]).  
E. granulosus has a worldwide distribution. CE is transmitted in domestic life 
cycles involving dog and livestock and constitutes an emerging public health 
problem especially in regions with extensive livestock husbandry and non-
supervised slaughter [2]. AE is endemic in the northern hemisphere and is 
 
Figure 1: Life cycle of E. granulosus (left-hand side) and E. multilocularis (right-hand 
side), picture from Wen et al. [1]. 
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transmitted in sylvatic life cycles involving foxes and small rodents. AE was 
considered to be rather rare because of limited contact between humans and 
wildlife. However, human AE can be extremely frequent particularly in foci 
where domestic dogs became involved in the life cycle as definitive hosts. 
Such reports exist from Alaska [3], People’s Republic of China [4] and Europe 
[5]. Recent reports demonstrate the spread of E. multilocularis in Europe after 
distinct increase in fox populations [5-7].  
 
Humans acquire infection by accidental ingestion of eggs from contaminated 
environment. The disease develops slowly. The latency period of AE is 
approximately 10-15 years [8]. Symptoms mainly occur when active cysts or 
metacestode tissue expand in size resulting in dysfunction of adjacent tissues 
or organs [9].  
 
The diagnosis of echinococcosis is based on the detection of cyst structures 
by imaging procedures, mainly ultrasound and computed tomography, and 
confirmation by immunodiagnostic tests demonstrating Echinococcus-specific 
antibodies. Hydatid cyst fluid is the antigenic source of reference for 
immunodiagnosis of human hydatidosis [10].  
 
ELISA using crude hydatid cyst fluid (EgHF) has a high sensitivity (75 - 95%), 
but its specificity is often unsatisfactory [10]. Cross-reactivity with sera from 
patients infected with other helminthic diseases is commonly observed (89% 
with other cestode infections, 30% with trematode infections and 39% with 
nematode infections) [11]. Specificity can be improved by using purified native 
antigen and/or alternative diagnostic techniques, such as immunoblotting.  
 
EgHF is a complex mixture of glyco- and lipoproteins, carbohydrates and salts 
[10]. Most of these molecules are of parasite origin, but also host components 
were found, e.g. host albumin and immunoglobulins. Antigen B and antigen 5 
are the diagnostically most important components of EgHF.  
 
Antigen 5 is synthesized as single polypeptide chain and is processed into 
single disulphide-bridged 22 and 38kDa subunits [12]. Applied in 
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immunoelectrophoresis, it produces the diagnostically relevant precipitation 
line termed “arc-5” [13]. A study comparing recombinant, native, and 
deglycosylated native antigen 5 showed the importance of post-translational 
glycosylations for the antigenicity of this protein [14]. Although the diagnostic 
value of antigen 5 has been thoroughly evaluated, there is only little 
knowledge in the biological function of this protein. Lorenzo and co-workers 
showed high similarity of antigen 5 with serine proteases of the trypsin family 
in terms of sequence conservation and secondary structure [12].   
 
Antigen B is a polymeric lipoprotein of 160kDa that aggregates from 8kDa 
subunits which are encoded by a multigene family. A recent study showed 
that this multigene family comprises at least five subfamilies and identified 10 
unique family members which were differentially expressed throughout the 
life-cycle [15]. This study also showed that antigen B genes were highly 
conserved even in isolates from distant geographical locations or from 
different hosts [15]. These findings contradicted previous reports claiming 
significant variation in antigen B family members isolated from different hosts 
[16-18]. The implication of this recently detected sequence conservation is 
that antigen B subunits can be considered valuable antigens for 
immunodiagnosis.  
 
The biological function of antigen B is no yet fully understood. A possible role 
of antigen B could be in the evasion of host immune response. Antigen B was 
shown to inhibit neutrophil chemotaxis [19] and to elicit a non-protective Th2 
immune response [20]. Applied in SDS-PAGE under reducing and non-
reducing conditions, antigen B dissociates into 8-12, 16 and 20-24kDa 
subunits [10]. Its smallest 8kDa subunit is highly antigenic and recognized in 
immunoblot by about 90% of patients with CE infection and 40% of patients 
with AE infections [21].  
 
The major issue of using native parasite material as main source of antigen is 
the lack of standardization due to the varying content of its components. It 
was shown that carbohydrate and lipid content were significantly different 
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between fertile and non-fertile cysts [22]. Thus source and fertility of cysts 
seem to be critical for test outcome.  
 
To overcome problems associated with native antigen, several recombinant 
antigens from both, E. granulosus and E. multilocularis have been produced 
and tested, for example recombinant E. multilocularis antigen II/3-10, which 
has a long history of successful application in diagnosis of human AE [23-25]. 
Recombinant E. granulosus B2t showed most promising results in the 
diagnosis of primary CE, but also in follow-up monitoring of treated CE 
patients in ELISA [26]. Recombinant E. granulosus elongation factor 1 
beta/delta was applied in IgE immunoblot and was found positive in 33% of 
surgically confirmed CE cases, which previously had been tested negative in 
routine diagnostic assays [27].  
 
The next step of further antigen development might consist in the chemical 
production of synthetic antigen. Through constant improvements of synthesis 
protocols, reagents and instruments, it has become possible to synthesize 
peptides of 100 - 150 amino acids in length on a routine basis [28]. Already 
much shorter peptides of about 20-25 amino acids in length were proven 
suitable antigens for the diagnosis of various infectious diseases, mainly of 
viral origin [29-31], but also of parasitic diseases [32-34]. 
 
Chemical synthesis of antigens may result in complete independence of 
native parasite material and biological expression systems and permits the 
production of GMP-grade test reagents. Benefits of synthetic peptides used as 
antigens are unlimited availability, stability and reproducibility. 
 
About 90% of antibodies induced by natural infection are directed against 
conformational epitopes, i.e. epitopes made up of amino acids that are not 
necessarily contiguous in the sequence, but are brought into spatial proximity 
by the folding of the polypeptide chain [35]. An estimated 10% of antibodies 
are directed against linear epitopes made of continuous amino acids. Linear 
epitopes usually have flexible unfolded conformations and are located in large 
unstructured loops or terminal protein regions [28].  
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Prerequisite for antibody recognition by synthetic antigens is their ability to 
adopt native antigen conformation. Among the short and structurally stable 
protein domains that are able to fold into their native structure even as 
isolated peptides are the alpha-helical coiled-coils (CC) and the intrinsically 
unstructured regions (IUR). IURs do not exhibit any particular folding, while 
CC have been shown in vitro to readily assemble into two- or three-stranded 
structures [36,37].  
 
Both, alpha-helical coiled-coils and intrinsically unstructured domains are 
frequent motifs. Possibly up to 30% of eukaryotic proteins are either 
completely or partially disordered [38]. Current estimates indicate that 
approximately 5-10% of sequences from the various genome projects encode 
coiled-coil regions [39]. A survey of GenBank entries revealed that in 
pathogens and parasites many extended coiled-coil domains (>75 amino 
acids in length) were external and binding to host proteins [40]. Detailed 
immunological studies showed alpha-helical coiled-coil proteins to possess 
antigenic characteristics [28,41,42]. Furthermore, the locations of alpha-helical 
coiled-coils and intrinsically unstructured regions can both readily be predicted 
by bioinformatic algorithms from the primary amino acid sequence of proteins.  
 
Taken together, CC and IUR domains predicted from Echinococcus 
granulosus and E. multilocularis proteins appeared as ideal candidate motifs 
to be tested as synthetic peptide antigens during this PhD thesis.  
 
General aim of this thesis  
The principal aim of this study was the establishment of a new discovery 
pathway for diagnostic peptides. The peptides were selected in silico by 
bioinformatics means complemented with immunological analysis on peptide 
microarray, a high-throughput screening method. Using a microarray format 
offers the advantages of low reagent consumption and rapid multiplexed 
analysis. In particular for the development and validation of new diagnostic 
tests, serum-saving methods are essential, because well characterized sera 
are rare and thus highly precious.   
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The project made use of publicly available sequences from Echinococcus 
granulosus and E. multilocularis.  
 
Specific objectives 
i. Development of bioinformatic procedures to assess and select peptides 
from a genome-wide, a proteome-wide and a transcriptome-wide analysis. 
ii. Establishment of a peptide microarray platform for the screening of 
diagnostic targets. 
iii. Determination of optimal length of synthetic peptide antigens. 
iv. Providing proof-of-principle for the suitability of the peptides selected for 
serological diagnosis of echinococcosis in ELISA format. 
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Figure S1:  
 
Alignment of E. granulosus and E. multilocularis antigen B8/1 sequences with 
location of peptide D8, D9 and longD8-9. 
 
 
 
 
 
 
 
Figure S2: 
 
Alignment of E. granulosus and E. multilocularis antigen B8/2 sequences with 
location of D11 and longD11. 
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Abstract 
The use of chemically synthesized antigens for infectious disease diagnostics 
represents a promising alternative to current tests based on crude or partially 
purified antigen extracts. Benefits of synthetic peptides are unlimited 
availability, stability and reproducibility. We aimed at characterizing proteins in 
the 20-22 kDa protein fraction of in vitro cultivated Echinococcus multilocularis 
vesicle fluid by mass spectrometry. From thus identified proteins 30mer 
peptides were bioinformatically selected and screened for reactivity with sera 
from echinococcosis patients. We identified 34 proteins in this fraction and 
selected 41 peptides for synthesis. Of these 14 were reactive with 
echinococcosis sera, 12 were omitted due to reactivity with echinococcosis 
negative control sera. The resulting 2 validated peptides individually do not 
present sufficient sensitivity, but have potential for inclusion in multiplexed 
assays.  
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Introduction 
Cystic and alveolar echinococcosis in humans are caused by the metacestode 
larvae of the closely related tapeworms Echinococcus granulosus and E. 
multilocularis. Successful establishment of the parasite leads to cyst 
development in liver, lungs or other organs. Cysts caused by E. granulosus 
are well-delineated, unilocular and fluid-filled. They consist of an inner 
germinal layer surrounded by a non-cellular laminated layer and host-
produced fibrous adventitial tissue [1]. In contrast, E. multilocularis causes the 
growth of a dispersed, spongy metacestode tissue consisting of scattered, 
small cysts without limiting host-tissue barrier [1,2]. Early diagnosis is 
important, because radical removal of metacestode tissue by surgery is 
considered the most successful treatment. But diagnosis very often is delayed 
because cysts develop slowly and little specific symptoms, such as abdominal 
pain, nausea, jaundice and feeling of exhaustion. Up to 50% of AE and CE 
cases may remain asymptomatic and parasite lesions would incidentally be 
detected during examinations for other diseases [1].  
 
Current routine diagnosis of human echinococcosis is based on imaging 
procedures (ultrasound, x-ray, computed tomography and magnetic 
resonance imaging) [1]. Immunodiagnostic techniques such as ELISA and 
immunoblotting are currently applied to confirm the presence of an 
Echinococcus cyst.   
 
The antigens used in current immunodiagnostic screening tests mainly 
originate from native E. granulosus cyst fluid collected from naturally infected 
intermediate hosts, e.g. cattle or sheep. Native antigens are limited in 
availability and their standardization is difficult to achieve. To overcome the 
limitations of the current diagnostic tests the present study aimed at identifying 
proteins that are generally well recognized by sera of human echinococcosis 
patients and to select from these immunodominant regions. We focused on 
the diagnostically sensitive and specific 20-22 kDa banding pattern seen on 
immunoblots of in vitro cultivated E. multilocularis vesicle fluid described by 
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Müller and co-workers [3] and aimed to identify its protein content by tandem 
mass spectrometry (MS).   
 
Our objective was to select protein domains for peptide synthesis that have 
the potential to structurally mimic native epitopes. We chose a bioinformatic 
approach for the selection of 30mer peptides whereby peptide length was 
limited by the micro-scale multi-peptide synthesis method (Alta Bioscience, 
University of Birmingham, UK). Within the proteins identified we searched for 
predicted alpha-helical coiled-coils (CC) and intrinsically unstructured regions 
(IUR). Synthetic peptides representing these two folding motifs are capable of 
adopting their native conformation in vitro [4]. Used as antigens in serological 
tests, peptides deriving from CC and/or IUR domains should therefore be able 
to present potential epitopes in their natural conformation.  
 
We chose to synthesize peptides instead of recombinant expression of the 
proteins identified by MS, because this approach could potentially lead to a 
diagnostic product in a very fast and efficient way. Most importantly, with this 
approach purification problems in the production of diagnostics grade 
recombinant antigen could be avoided. Synthetic antigens are advantageous 
because they are highly pure, well-defined and can be produced in large 
amounts. Moreover, synthetic antigens can easily be standardized and 
consequently, immunodiagnostic tests using synthetic peptides may provide a 
basis for consistent diagnosis comparable among different laboratories. 
Synthetic peptides have been tested already in a wide range of diagnostic 
applications and proved valuable for diagnosis of viral diseases (reviewed e.g. 
in [5-7]).  
 
New systems for parallel detection of individually labeled and multiplexed 
analytes are well suited for synthetic peptides, which by chemical modification 
can easily be coupled to microbeads or glass slides. The expected loss of 
sensitivity in peptide-based immunoassays might be compensated by 
multiplexing of analytes. Here we investigate first steps towards peptide-
based serological assays by applying a proteomic strategy to identify 
immunologically relevant antigens. For Echinococcus as well as for many 
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other helminthic parasites very little genomic data is available. The presented 
strategy could pave the road for similar diagnostic tasks.  
Materials and methods 
Human sera 
The echinococcosis sera derived from 33 CE and 43 AE adult patients living 
in Central Europe. All patients had active hepatic lesions of either CE1 or CE2 
type (WHO-IWGE standardized classification). Echinococcosis infections were 
diagnosed as described by Müller et al. [3]. All samples were collected prior to 
therapeutic intervention, i.e. before surgery and/or chemotherapy.  
 
To test whether the peptides selected were cross-reactive with sera from 
other parasitic infections, 74 sera were used. 2 patients were infected with 
Trichinella spiralis, 10 with Toxocara canis, 6 with Ascaris spec., 1 with 
Anisakis spec., 1 with hookworms, 7 with Strongyloides stercoralis, 4 with Loa 
loa, 1 with Mansonella perstans, 2 with Onchocerca volvulus, 9 with Fasciola 
hepatica, 1 with Paragonismus westermani, 7 with Schistosoma mansoni, 2 
with S. haematobium, 1 with S. mekongi, 10 with Taenia solium and 10 with 
Entamoeba histolytica. Concomitant echinococcosis was ruled out by clinical 
and serological criteria.  
 
A total of 89 serum samples from healthy blood donors living in Switzerland 
were used for cut-off calculation to discriminate between positive and negative 
test results ( n=52), specificity testing (n=35) and as negative controls (n=2).  
 
Ethical clearance for retrospective use of anonymized patient sera for test 
development and quality control was obtained from the ethical committee 
(Ethikkommission beider Basel).  
 
Antigen, immunoblotting and NanoLC ESI-MS/MS 
Vesicle fluid was obtained by aseptic aspiration from E. multilocularis 
metacestodes axenically cultivated as described by Hemphill et al. [8]. The 
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vesicle fluid (EmVF) was processed as described by Müller et al. [3] and 
stored at -80°C until use. EmVF was mixed with SDS sample buffer (10mM 
Tris/HCl pH 8.0, 9M urea, 10% SDS), incubated for 20 minutes at 65°C and 
electrophoretically separated in either a 5-20% linear gradient polyacrylamide 
gel or in a 15% polyacrylamide gel. One half of each gel was silver stained 
(Sigma SilverQuest LC6070). The separated proteins in the other half were 
electrotransferred onto nitrocellulose membrane as described by Poretti et al. 
[9]. Nitrocellulose membranes were incubated with serum from a patient 
infected with E. multilocularis to visualize the diagnostically sensitive and 
infection-specific 20-22 kDa banding pattern described by Müller et al. [3]. 
Using the immunoblot for orientation, three silver-stained bands 
corresponding to the region of the diagnostic banding pattern were excised 
from SDS-gels. One band (band A) derived from a 15% gel, two bands from a 
5-20% gradient gel (band B and C). Gel slices were sent for NanoLC ESI-
MS/MS analysis (Proteomics Core Facility, University of Geneva, 
Switzerland).  
 
Immunoblots produced from EmVF separated in a 5-20% gradient gel as 
described above were cut into strips of 4mm width. 4 of these strips were 
incubated with rat anti-P29, negative rat control serum, mouse anti-14-3-3 and 
mouse negative control serum. All primary antibodies were diluted 1:400 in 
blocking solution (PBS, 2% skim milk, 0.1% Tween20 and NaN3) and 
incubated over night at 4°C. Blots were washed 4 times for 5 minutes in PBS 
0.1% Tween20. The secondary antibodies, IRDye800-conjugated goat anti-
mouse IgG and IRDye800-conjugated goat anti-rat IgG (Li-Cor Biosciences, 
Lincoln, USA) were diluted 1:5’000 in Odyssey blocking buffer (Li-Cor 
Biosciences) for 1 hour at room temperature in the dark, followed by 2 washes 
with PBS-Tween and 2 washes with PBS prior to scanning in an Odyssey 
Infrared Imaging System (Li-Cor Biosciences).  
 
Two more strips were incubated with human E. multilocularis positive and 
negative control serum and conventionally developed with anti-human IgG-
horseradish peroxidase as described previously [9].  
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Database search 
The spectra resulting from MS/MS analysis were searched against the Uniprot 
Protein Knowledgebase release 15.10 of November 3rd 2009 as well as 
against translations of the E. multilocularis and E. granulosus EST libraries 
available at the Wellcome Trust Sanger Institute (ftp://ftp.sanger.ac.uk/ 
pub/pathogens/Echinococcus/) by using the MASCOT search engine 
(MATRIX Science, London, UK). Scaffold (version Scaffold_2_05_01, 
Proteome Software Inc., Portland, USA) was used to validate MS/MS based 
peptide and protein identifications. Peptide and protein identification 
probabilities were assigned by the PeptideProphet and the ProteinProphet 
algorithm [10,11]. Peptide and protein identifications were accepted if the 
probability of correct identification was >95% and at least two peptides per 
protein were detected.  
 
Peptides 
Protein and translated EST sequences identified by MS/MS analysis served 
as parent proteins for peptide design. 41 peptides between 24 and 30 amino 
acids in length were selected according to rules published previously [12]. 
Parent protein sequences were analyzed by different algorithms to identify 
regions of stable alpha-helical coiled-coils (Paircoil2 [13], StableCoil [14] and 
intrinsically unstructured regions (IUPred [15], RONN [16]). Protein sequences 
without CC predictions were further analyzed for potential B-cell epitopes 
(BepiPred [17]).  
 
Peptides were produced by Fmoc solid phase synthesis (Alta Bioscience, 
University of Birmingham, UK). They contained an additional biotin used for 
immobilization onto streptavidin coated ELISA plates (NUNC immobilizer 
streptavidin) attached via a PEG spacer at the N-terminus. The C-terminus 
was amidated. The peptides were supplied as crude synthesis product. 
Peptide concentrations given in this work assume a consistent yield of 1mg of 
full-length peptide for each synthesis reaction.  
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ELISA 
ELISAs were performed in 96-well plates (NUNC Immobilizer Streptavidin)  as 
described elsewhere [12] with the following modifications: in initial screening 
ELISAs all 41 peptide candidates were coated at a concentration of 2ug/ml. 
Optimal coating concentration was determined for the most promising 
candidates C2 and B6 by peptide titration. For both peptides, the optimal 
coating concentration was 0.5ug/ml.  
 
The absorbance was measured at 405nm (A405) in a VERSAmax microplate 
reader. The raw data was transferred into Microsoft Excel and blank 
corrected. A cut-off value was calculated from results obtained from 52 
healthy blood donors as average blood donor A405 value plus 2 standard 
deviations  
 
The sensitivity (true positives / true positives + false negatives) was calculated 
for AE and CE sera together. All test blood donor samples (n=35) together 
with the samples from helminthic infections other than echinococcosis (n=64) 
served for calculation of specificity (true negatives / true negatives + false 
positives).  
 
Results 
NanoLC ESI-MS/MS 
The proteins identified with a corresponding Uniprot entry varied between 24 
and 49 kDa. All translated ESTs identified by MS/MS were subjected to a 
protein BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). If the blastp 
search returned protein hits with more than 40% similarity to the EST query, 
the blastp hits were used to characterize the corresponding EST sequence, 
otherwise the translated EST was termed “unknown protein product”. Protein 
sequences identified and selected for peptide design are listed in table 1, 
together with the blastp hits of the corresponding EST queries. 
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Regarding the number of unique peptide spectra found by MS/MS analysis, 
the most abundant proteins in bands A, B and C were members of the 14-3-3 
protein family. We designed therefore 15 peptides from 4 different 
conceptually translated 14-3-3-like EST sequences (table 2). The second 
most abundant protein was phosphoglycerate mutase, which was found in 
band A and B. It served as parent protein for 3 peptides (table 2). Antigen 6 
(accession no. AAB61984) was the third most abundant protein, but was 
excluded from peptide design, because we had previously investigated 
Antigen 6 derived peptides [12]. In these analyses, antigen 6 peptides had 
shown only little reactivity with sera from echinococcosis patients. Following 
proteins served for the design of ≤ 3 peptides: thioredoxin peroxidase, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), TSP5, cytosolic 
malate dehydrogenase, lactate dehydrogenase, elongation factor 1 alpha, 
proliferating cell nuclear antigen (PCNA), purine nucleoside phosphorylase, 
uridine cytidine kinase I, proteasome subunit alpha 7 and three different 
unknown protein products (table 2).  
 
For the selection of parent proteins, priority was given to E. multilocularis 
sequences, but the majority of the peptides designed could also be detected 
in E. granulosus EST sequences. Thus 17 peptides were 100% identical 
between E. multilocularis and E. granulosus. 9 differed in one, two or three 
amino acids. 10 peptides were E. multilocularis-specific, 2 peptides were E. 
granulosus-specific and 3 peptides could only partially be identified in E. 
granulosus libraries because of incomplete EST reads (table 2). 
 
Immunoblot 
Strips of EmVF immunoblots incubated with human echinococcosis positive 
and negative control sera are shown in figure 1. The arrow marks the main 
band visible in the 20-22 kDa diagnostic relevant region.  
 
To confirm the presence of 14-3-3 and P29 identified by tandem mass 
spectrometry, we used hyperimmune sera from mouse and rabbit immunized 
with recombinant 14-3-3 and P29 respectively. Strips from the same EmVF 
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immunoblot as used for incubation with human control sera (see above) were 
incubated with the respective mouse and rabbit sera. Both, anti-recP29 and 
anti-rec14-3-3 hyperimmune sera showed a distinct banding pattern in the 
diagnostically relevant region (figure 2). The pattern of rat anti-recP29 was 
more alike the pattern produced by sera of human echinococcosis patients 
than the pattern of mouse anti-14-3-3. Depending on the batch of EmVF used 
for immunoblotting, human echinococcosis sera produce a more or less 
pronounced banding pattern of up to three bands with a rather fuzzy 
appearance. This pattern could be caused by the overlay of several different 
proteins reactive with echinococcosis sera, for example by the upper band of 
P29 and the lower band of 14-3-3. Since the diagnostic value of P29 has 
already been investigated [18,19] and because the performance of our P29 
peptides investigated previously [12] was not satisfactory, we decided to leave 
P29 and to focus instead on 14-3-3 and the other proteins identified by 
MS/MS.  
 
ELISA 
The 41 peptide candidates were first assessed with 3 pools of AE and 3 pools 
of CE sera (5 sera in each pool). 14 out of 41 peptides yielded an A405-value ≥ 
0.150 after 20 minutes of incubation with substrate were selected for testing 
with individual sera from AE and CE infected patients (3 of each) and 1 blood 
donor serum. 8 of these 14 peptides were also reactive with single AE and CE 
sera and were further tested with an extended serum panel including 
additional echinococcosis sera, additional blood donor sera and additional 
sera from other helminthic and Entamoeba histolytica infections.  
 
The most promising peptides, B6 deriving from phosphoglycerate mutase and 
C2 deriving from cytosolic malate dehydrogenase (cMDH), were tested with 
the entire serum panel. The results are listed in table 3. The cut-off A405 
values were 0.196 for B6 and 0.114 for C2. Both peptides corresponded to an 
E. multilocularis sequence, but were equally reactive with sera from AE and 
CE patients and therefore were not able to discriminate between AE and CE 
infection. A blastp search in the collection of translated ESTs confirmed that 
46
CHAPTER 2 
 
peptides C2 and B6 were completely identical in both Echinococcus species. 
Peptide C2 was detected in following EST libraries: Emme (E. multilocularis 
metacestode; ligation numbers 90724, 90725, 90726, 90727), EMmg (oligo-
capped cDNA library from the metacestode (germinal layer) of E. 
multilocularis) and EGCWgr (oligo-capped cDNA library from the cyst wall of 
E. granulosus). Peptide B6 was found in Emme, EGPSPsl (spliced-leader 
cDNAs library from pepsin-treated E. granulosus protoscoleces) and 
EGPSPgr (oligo-capped cDNA library from the protoscolex stage of E. 
granulosus).   
 
The sensitivities of both peptides were low, 15% for C2 and 18% for B6. 
However, their reactivity was complementary and thus the sensitivity 
increased to 27% if the results of the two peptide ELISAs were cumulated.  
 
The specificities of the peptides were high, 90% for C2 and 91% for B6. 
Crossreactivity with neurocysticercosis was observed in both peptides: 2/10 
samples were positive with C2 and 1/10 with B6. 2/34 sera from nematode 
infections, 2/20 sera from trematode infections and 2/10 sera from Entamoeba 
histolytica infections were tested positive in C2 ELISA. In B6, 4/34 nematode 
and 2/20 trematode samples were positive (table 3). Regarding the cumulated 
specificity of the two peptides, the value decreased to 82%.  
 
Discussion 
Considerable efforts have been made in order to improve the performance of 
antigens for the diagnosis of human echinococcosis by purifying fractions from 
crude extracts, e.g. the Em2 fraction from metacestode tissue or antigen 5 
enriched cyst fluid. Recombinant antigens, such as EmII/3-10 and antigen B, 
were introduced into serological diagnosis. The application of recombinant 
antigens is advantageous because they can readily be produced in large 
amounts, while affinity purification of native antigens is time-consuming and 
often producing low yields [20]. A consequent further development would lead 
to replacement of both, native and recombinant antigens by chemically 
synthesized antigens, such as the 30 amino acids long peptides investigated 
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in this study. The added value of developing synthetic antigen consists in high 
reproducibility and purity, and also in the versatility of modified or labeled 
synthetic peptides, thus permitting the choice of alternative diagnostic 
detection systems, such as multiplex bead-based suspension assays. The 
recent developments of new platform technologies calls for defined analytes 
suitable for multiplexing.  
 
Aiming at the discovery of peptides reactive with human echinococcosis sera, 
we followed a proteomic approach. We targeted the antigens seen at the 20-
22 kDa region on immunoblots of in vitro cultivated E. multilocularis vesicle 
fluid. Reactivity of patients’ sera with the 20-22 kDa banding pattern has been 
described as a marker for Echinococcus infection [3]. The protein content of 
this region cut out in 3 fragments was analyzed by tandem mass spectrometry 
and database mining. 
 
One major challenge was the complexity of the protein mixture, 34 proteins 
were identified in the three bands subjected to mass spectrometry, 23 of 
which were found only by searching peptide spectra against our database of 
theoretical proteins conceptually translated from EST libraries, which are 
available at the Wellcome Trust Sanger Institute (ftp://ftp.sanger.ac.uk/pub/ 
pathogens/Echinococcus/). Thus, in the case of an organism without (yet) 
sequenced genome, protein identification can be considerably improved by 
the use of EST libraries.  
 
The number of trypsin fragments detected from a protein identified hints at its 
relative abundance in the excised gel fragment. But abundance does not 
correspond to antigenicity. Therefore a second round of immunological 
screening was required. The 41 peptide candidates were screened for 
reactivity with patients’ sera in the well-proven ELISA system.  
 
Among the proteins identified were the functionally diverse 14-3-3 family 
members. Echinococcus 14-3-3 homologue 1 and 2 were represented by the 
highest number of unique peptide spectra. Members of the 14-3-3 protein 
family were detected in all eukaryotes examined so far. The 14-3-3 family was 
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found to be involved in a wide range of functions including cell signaling, cell 
cycle regulation, metabolism control, apoptosis, gene transcription, 
intracellular trafficking and cytoskeletal structure [21]. In E. multilocularis the 
14-3-3 protein was first detected by immunoscreening of an expression library 
of metacestode cDNA [22]. The protein was found to be 10-fold 
overexpressed in the metacestode stage when compared to expression levels 
in the adult tapeworm. In multiple sequence alignment the Echinococcus 
sequence clustered with the zeta isoforms, which are known to be related to 
tumor growth [23]. It has been suggested that the 14-3-3 protein might be 
involved in the infiltrative and potentially unlimited, tumor-like growth behavior 
of the E. multilocularis metacestode larva within the host tissue [22,23]. 
 
We also detected in the 20-22 kDa banding pattern proteins that were 
previously investigated for their antigenic properties in echinococcosis, such 
as antigen 6 (which shows 97% identity to E. granulosus antigen P29 [18]), 
cytosolic malate dehydrogenase [24,25], TSP5 [26], and thioredoxin 
peroxidase [27].  
 
The detection of antigen 6 in E. multilocularis vesicle fluid was unexpected.  
Antigen P29 of E. granulosus, the putative antigen 6 orthologue, was 
identified in a study aimed deliberately at the discovery of antigens distinct 
from those contained in hydatid cyst fluid [18]. Immunoblotting with parasite 
extracts and immunofluorescence on parasite sections revealed the 
localization of P29 to protoscoleces and the germinal layer of the 
metacestode. It was absent from adult worms and from hydatid cyst fluid [18]. 
Thus, assuming E. multilocularis antigen 6 to be the orthologue of E. 
granulosus P29, our MS/MS-based identification approach gives evidence for 
the differential localization of a homologous protein within the two closely 
related tapeworms. 
 
The cytosolic malate dehydrogenase (cMDH) of Echinococcus granulosus 
was as well found by immunoscreening of a protoscolex cDNA expression 
library [24]. All eukaryotes posses two forms of malate dehydrogenase, a 
cytosolic (cMDH) and a mitochondrial (mMDH) one. Malate dehydrogenases 
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are important enzymes of the citric acid cycle and gluconeogenesis. The 
Echinococcus cMDH was recombinantly expressed and assessed as 
diagnostic antigen in ELISA and immunoblot [25]. Due to its rather low 
sensitivity of 54%, the authors suggested to use the recombinant cMDH in 
combination with a panel of several defined antigens for the improved 
diagnosis of human echinococcosis [25]. Later on, recombinant cMDH was 
part of such an antigen panel tested in a multicenter study in South America. 
In this study, recombinant cMDH performed worse than expected and 
produced inconsistent results between the participating centers [28]. The 
authors therefore agreed the now commonly accepted fact that comparability 
of antigen performance needs standardization in respect to sera used and 
antigen preparation [28].  
 
Three more proteins identified in the diagnostically relevant region were 
known from the glycolytic pathway and were reported antigens from other 
parasitic organisms: GAPDH in Schistosoma mansoni [29], lactate 
dehydrogenase in Plasmodium spec. [30] and phosphoglycerate mutase in 
Candida albicans [31]. Phosphoglycerate mutases are essential enzymes in 
glycolysis and are found in bacteria, fungi, plants and animals. Their benefit 
as diagnostic markers has not yet been investigated in detail. In contrast to 
few records on antigenicity, phosphoglycerate mutases and other enzymes of 
the glycolytic pathway appear as useful drug target in different parasites, such 
as flukes [32] and nematodes [33] but also Trypanosoma and Leishmania 
[34,35].  
 
Further proteins identified were purine nucleoside phosphorylase which had 
been discovered as potential biomarker for trichloroethylene-induced 
autoimmune disease in humans [36] and proliferative nuclear cell antigen 
(PCNA) a protein considered as biomarker for human systemic lupus 
erythematosus [37]. The diagnostic banding pattern contained also few 
proteins that had not been investigated as potential antigens, namely 
elongation factor 1 alpha (BAF63674), uridine cytidine kinase I and 
proteasome subunit alpha 7. Some peptide spectra matched no Uniprot entry, 
but EST-sequences only. These sequences were of particular interest for 
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peptide design, because they represented proteins possibly unique to 
Echinococcus and thus were of great interest for the application in 
diagnostics. 
 
The previous characterization of the 20-22 kDa diagnostic banding pattern 
with specific antibodies had shown that this region of the immunoblot did not 
contain any degradation forms of EmII/3, whereas the full-length EmII/3 
appeared at the expected size of 65 kDa [3]. Our data supports this finding 
since EmII/3 was not detected in any of the bands analyzed.  
 
In conclusion, it was not possible to tell from the list of proteins identified 
which was (were) the one(s) responsible for the specific reaction seen on 
immunoblot. As mentioned before, the estimated abundance of protein 
contained in the gel slices did not correspond with antigenicity. The 14-3-3-
proteins identified by the highest number of unique peptides failed in ELISA. 
Only one 14-3-3-candidate, peptide A2, showed weak reactivity in first 
assessments, but had to be dismissed due to low sensitivity.  
 
All other known Echinococcus proteins on the list which had previously been 
tested as antigens in immunoblot or ELISA showed inferior operating 
characteristics than the still unknown EmVF protein(s) in the 20-22 diagnostic 
banding pattern [18,24,27]. In addition, our screening ELISA was not able to 
identify peptides with comparable high sensitivity and specificity. A reason for 
this might be the nature of the epitopes sought after. In case the diagnostically 
relevant targets are mainly composed of carbohydrate epitopes, it will not be 
possible to reproduce these epitopes with simple synthetic peptides. On the 
other hand, the relevant epitopes might be of proteinaceous nature, but be 
part of a secondary structure that cannot be adopted by synthetic 30mer 
peptides. Another shortcoming of synthetic peptides might be the destruction 
of epitopes caused by the selection of peptide location. A peptide might start 
or end amidst the amino acids constituting an epitope and thereby destroy the 
site recognized by antibodies. The testing of several highly overlapping 
peptides might be chosen to counter this issue. Our results, in particular the 
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immunoblot with rat anti-recP29, strongly suggest considering overlapping 
peptides for a more detailed analysis of antigen 6 or P29, respectively.  
 
Taken together, inference from the peptide antigens tested in the present 
study on the identity of the 20-22 kDa protein(s) cannot be made. Nonetheless 
two new peptides with potential for application in serodiagnosis of human 
echinococcosis have been discovered.  
 
Besides the complexity of the protein content of the three bands tested by 
mass spectrometry, the second challenge of our approach consisted in the 
selection of antigenic domains within the identified proteins and translated 
ESTs. Our peptide design was guided by the predictions of alpha-helical 
coiled-coils (CC) and intrinsically unstructured regions (IUR). Proteins without 
predicted CC were further analyzed with BepiPred, an algorithm for the 
prediction of linear B-cell epitopes. Alpha-helical coiled-coils and intrinsically 
unstructured regions are believed to adopt native conformation if chemically 
synthesized and therefore synthetic peptides corresponding to these two 
motifs potentially could represent native epitopes.  
 
The most reactive peptides discovered in our screening ELISA were peptide 
C2 from Echinococcus cMDH and peptide B6 originating from a member of 
the phosphoglycerate mutase family.  
 
Regarding cMDH, we designed and tested two peptides: peptide C2 (27 
amino acids in length) and C3 (28 amino acids). A blastp search within the 
translated EST libraries revealed that C2 was 100% identical in E. 
multilocularis and E. granulosus while peptide C3 differed in one amino acid. 
In ELISA, the sensitivity of peptide C2 was as low as 15% in, but specificity 
was high with 90%. C3 was discarded early in the screening procedure 
because it showed no reactivity with patients’ sera. From the 
phosphoglycerate mutase sequence, we designed and tested three different 
30mer peptides: B5, B6 and B7. Peptide B5 was non-reactive with patients’ 
sera. B6 achieved a low sensitivity of 18%, but a high specificity of 91% and 
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B7 showed reactivity only with a pool made of CE sera, but not with single 
patients’ sera.  
 
Low sensitivity was the major shortcoming of the synthetic peptides identified 
and tested. This clearly precludes the use of a single peptide for diagnostic 
purposes, and combination of several peptides to create a complex antigen 
mixture is required. The limited length of the peptides could explain the 
observed low sensitivity because 30 amino acids potentially harbor less 
epitopes than 300 amino acids of an average full-length protein. This is 
supported by our previous characterization of another E. multilocularis peptide 
[12], a 42mer peptide originating from antigen B8/1. This peptide covers 
almost two thirds of the length of its parent protein (65 amino acids) and 
together with a closely related peptide p176 [38] represents to our knowledge 
the most sensitive synthetic peptides tested so far in the diagnosis of 
echinococcosis.  
 
Our results demonstrate a new approach in the search for diagnostic peptides 
by MS combined with bioinformatics. While individual peptides do not provide 
sufficient sensitivity suitable for a diagnostic routine test, peptide-pools could 
have the potential to compensate this limitation.  
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Figures 
 
Figure 1:  
 
Immunoblot of human echinococcosis positive (strip1) and 
negative (strip 2) control sera; the arrow indicates the main band 
visible in the diagnostically relevant region.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  
 
Immunoblot incubated with 1) pre-immune 
rat serum, 2) serum from rat immunized with 
recombinant E. granulosus P29, 3) pre-
immune mouse serum and 4) serum from 
mouse immunized with recombinant E. 
granulosus 14-3-3.  
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Table 3:  
Assessment of peptides C2 and B6 in ELISA with sera from healthy blood 
donors, echinococcosis patients, patients infected with other helminths and 
amoebic liver abscess.  
 
  C2 B6 
Cut-off   0.114 0.196 
    
Healthy n total n positive n positive 
Blood donors 35 4 2 
    
Cestode infection       
Echinococcus multilocularis 42 8 6 
Echinococcus granulosus 32 3 7 
Taenia solium 10 2 1 
    
Nematode infection       
Trichinella spiralis 2 0 0 
Toxocara canis 10 1 2 
Anisakis spec. 1 0 0 
Hookworm 1 0 0 
Strongyloides stercoralis 7 0 0 
Loa loa 4 1 1 
Mansonella perstans 1 0 0 
Onchocerca volvulus 2 0 0 
Ascaris spec. 6 0 1 
    
Trematode infection       
Paragonymus westermani 1 0 0 
Fasciola hepatica 9 0 1 
Schistosoma mansoni 7 0 1 
Schistosoma haematobium 2 1 0 
Schistosoma mekongi 1 1 0 
    
Amoeba infection       
Entamoeba histolytica 10 2 0 
    
 
 
 
 
 
 
 
 
63
  
64
CHAPTER 3 
 
 
 
 
Chapter 3:  
Diagnostic value of alpha-helical coiled-coil peptides 
for immunodiagnosis of human echinococcosis 
 
 
 
Claudia List 1,3, Christoph Schmid 2,3, Ingrid Felger 1,3 
 
 
 
1 Swiss Tropical and Public Health Institute, Molecular Diagnostics, Basel, 
Switzerland 
2 Swiss Tropical and Public Health Institute, Biostatistics and Computational 
Sciences, Basel, Switzerland 
3 University of Basel, Basel, Switzerland 
 
Manuscript in preparation for publication. 
 
 
65
CHAPTER 3 
 
Abstract 
The main source of antigen used in routine serodiagnosis of human 
echinococcosis is hydatid fluid of Echinococcus granulosus cysts collected 
from naturally infected intermediate hosts, e.g. sheep and cattle. Native and 
recombinant antigens are valuable reagents because they contain a big 
variety of epitopes, but they generally harbor also cross-reactive epitopes 
which in turn compromise test specificity. To avoid any further dependency on 
non-standardized native parasite material, effective strategies were sought for 
in silico selection of immunodominant epitopes that can be mimicked by 
chemically synthesized peptides. We investigated the diagnostic potential of 
alpha-helical coiled coil (CC) peptides predicted from conceptually translated 
Echinococcus spp. EST reads available at the Wellcome Trust Sanger 
Institute (ftp://ftp.sanger.ac.uk/pub/pathogens/Echinococcus/). From the 2 E. 
multilocularis and the 5 E. granulosus EST libraries, a total of 158 non-
redundant sequences were predicted to contain one or more CC domains of 
at least 30 amino acids in length. 53 different 30mer peptides were selected 
and screened for reactivity with patients’ sera on a microarray platform. 18/53 
peptides exhibited reactivity on microarray. 8/18 peptides were also reactive 
with sera from echinococcosis patients in ELISA. 7 of these peptides were 
discarded because of too little reactivity with echinococcosis sera or strong 
cross-reactivity with non-echinococcosis sera. Peptide MA2_H3 emerged as 
best performing candidate. It proved to be E. multilocularis specific and 
reached a sensitivity of 29% for the diagnosis of alveolar echinococcosis (AE) 
and a specificity of 96%. While such a low sensitivity seems inadequate for a 
diagnostic test based on this peptide alone, it is a valuable candidate for 
inclusion into a multi-peptide assay on the grounds of its high specificity.   
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Introduction 
Future developments in serological diagnostics likely consists in highly pure 
and synthetic analytes and reagents in combination with new detection 
techniques compatible with multiplexing of diagnostic targets. The selection 
and production of synthetic antigens such as chemically synthesized peptides, 
which mimic immunodominant epitopes, would represent a logical step into 
the next generation of diagnostic tools.   
 
Synthetic peptides are highly pure, well-defined and thus reproducible. Assays 
based on synthetic peptides can be standardized easily in any lab as the 
starting material for test production is of consistent quality and also relieves of 
dependency on parasite material for antigen production. In the past, 
considerable efforts have been made to develop such synthetic reagents for 
immunodiagnosis. Synthetic peptides have been applied in diagnosis of a 
wide range of infectious and autoimmune diseases (reviewed e.g. in [1,2]). 
Promising results were obtained especially in diagnostics of viral infections 
such as HIV [3], SARS-CoV (severe acute respiratory syndrome associated 
coronavirus) [4], Rubella virus [5] and others, but also in bacteria, e.g. 
Chlamydia trachomatis [6] and Mycobacterium tuberculosis [7] and the 
protozoan parasite Toxoplasma gondii [8]. Synthetic peptides for the 
diagnosis of helminthic infections have been reported for example from the 
nematode Wuchereria bancrofti [9], the trematodes Fasciola hepatica [10] and 
Schistosoma mansoni [11] and the cestodes Taenia solium [12] and 
Echinococcus granulosus [13].   
 
Successful application of peptide antigens depends on their ability to mimic 
native epitopes. The majority of native epitopes is conformational [14]. In the 
present work, we have tested the diagnostic potential of peptides 
corresponding to alpha-helical coiled-coil domains. This folding motif is readily 
adopted by synthetic peptides in vitro [15], and hence likely mimics the native 
conformation of the synthesized sequence. Alpha-helical coiled-coils are 
among the most common conformations found in proteins and are either of 
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fibrous or globular type [16]. Current estimates indicate that approximately 5-
10% of sequences from the various genome projects encode coiled-coil 
regions [17]. A survey of GenBank entries revealed that in pathogens and 
parasites many extended coiled-coil domains (>75 amino acids in length) 
were external and binding to host proteins [18]. Detailed immunological 
studies showed alpha-helical coiled-coil proteins to possess antigenic 
characteristics [19-21].  
 
A heptad repeat underlies alpha-helical coiled-coils. This motif is denoted 
(abcdefg)n, whereby positions a and d are usually occupied by nonpolar 
residues. This arrangement places the hydrophobic residues at one face of 
the alpha-helix promoting its association with a complementary surface to 
form a left-handed supercoil [18]. In absence of an interchain disulphide 
bridge, the minimal requirement in peptide length for formation of stable two-
stranded alpha-helical coiled-coils was 3 heptad repeats [22], i.e. 21 amino 
acids. Such length can readily be achieved by chemical synthesis.  
 
For this study all EST libraries currently available in the public domain were 
downloaded and conceptually translated. Because to date no assembly of any 
Echinococcus genome is available, the EST libraries constitute the only 
source for genome-wide data mining. Bioinformatic secondary structure 
prediction was applied to select for peptides with high predicted probabilities 
to form alpha-helical coiled-coils. The aim was to identify novel diagnostic 
reagents and to validate the genome-wide approach to antigen prediction for 
identification of diagnostic peptides. The underlying hypothesis was that not 
only the native conformation would be mimicked by these 30mer synthetic 
peptides, but also native epitopes that are reactive with patients’ sera. 
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Materials and methods 
Bioinformatics 
All EST libraries available at the Wellcome Trust Sanger Institute 
(ftp://ftp.sanger.ac.uk/pub/pathogens/Echinococcus/) were downloaded. Two 
approaches were used for their conceptual translation: i) a Perl script, which 
translated all 6 frames and selected the longest open reading frame (ORF) as 
definitive translation and ii) the FrameDP algorithm, which was developed by 
Gouzy and co-workers to predict coding sequences in “noisy” transcripts with 
possible frameshifts and despite missing start/stop codons [23]. Output data 
of both algorithms were combined and used as theoretical protein database 
for both Echinococcus species. The quality of this database was assessed by 
a blastp query [24] for several arbitrarily selected Echinococcus spec. 
sequences: antigen B1 and B2 (Uniprot Q5EKQ4 and D1MH06), EmII/3 
(Uniprot Q05768), P29 (Uniprot Q9U8G7), protoscolex specific coiled-coil 
protein (Uniprot Q8I7B6) and EM13 (Uniprot Q07840).  
 
The highly redundant theoretical protein database was used as input for 
alpha-helical coiled-coil (CC) prediction by Paircoil2 [25]. To eliminate 
redundancy, each predicted CC domain of at least 30 amino acids in length 
was blasted against the full data set of predicted CC domains. Three 
categories were created: group 1 contained sequences for which both the Perl 
and FrameDP algorithm had produced identical translations and which 
matched to only one EST read. Group 2 contained sequences with identical 
Perl and FrameDP translations, but matches were found with more than one 
EST reads with few amino acids difference. Group 3 sequences were 
detected either in the Perl or the FrameDP translation only.  
 
In total, 158 sequences with predicted CC-domains were selected from 
groups 1-3 and submitted to further analysis by StableCoil, an algorithm 
designed to predict not only the location, but also the relative stability of 
coiled-coils [26]. Peptide sequences for chemical synthesis were selected 
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from stretches of overlapping Paircoil2 and StableCoil prediction from group 1 
and 2 proteins. 
 
Peptide synthesis 
Peptides were produced by Fmoc solid phase synthesis with C-terminal 
amidation (Alta Bioscience, University of Birmingham, UK). The batch 
synthesis procedure limited the length of the peptides to 30 amino acids. All 
peptides received an N-terminal biotin attached via PEG-spacer. Thus, both 
N-terminal and C-terminal peptide ends were uncharged, mimicking natural 
segments of internal protein sequences. Biotin was used to immobilize the 
peptides onto a streptavidin-coated surface, i.e. microscope glass slide for 
microarrays or 96-well plates for ELISA.  
 
Peptides were supplied as crude synthesis product. In the absence of 
specification of peptide concentration, a consistent yield of 1mg of full-length 
peptide was assumed. 
 
Human sera 
Ethical clearance for retrospective use of anonymized patient sera for test 
development and quality control was obtained from the ethical committee 
(Ethikkommission beider Basel).  
 
The echinococcosis sera used in this study consisted of samples from 33 CE 
and 43 AE adult patients living in Central Europe. They were the same serum 
samples as used in a previous study [27]. All patients had active hepatic 
lesions of either CE1 or CE2 type (WHO-IWGE standardized classification). 
Echinococcosis infections were diagnosed as described by Müller et al. [28]. 
All samples were collected prior to any therapeutic intervention, i.e. before 
surgery and/or chemotherapy.  
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In order to test whether  peptides were also recognized by sera from patients 
infected with other helminths than Echinococcus spec., the following 74 sera 
were used: 2 trichinellosis, 10 toxocariasis, 6 ascariasis, 1 anisakiasis, 1 
hookworm infection, 7 strongyloidiasis, 7 filariasis (Loa loa, Mansonella 
perstans, Onchocerca volvulus), 9 fascioliasis, 1 paragonimiasis, 10 
schistosomiasis (Schistosoma mansoni, S. haematobium, S. mekongi), 10 
neurocysticercosis (Taenia solium) and 10 amoebic liver abscess (Entamoeba 
histolytica). Concomitant echinococcosis in these 74 patients was ruled out by 
clinical and serological criteria. 
 
Serum samples from healthy blood donors living in Switzerland were used for 
cut-off calculation to discriminate between positive and negative test results (n 
= 8 in microarray assay; n= 52 in ELISA), specificity testing (n = 35 in ELISA) 
and as negative controls in ELISA (n = 2). 
 
Microarray 
Microarray slides were spotted by Alta Bioscience, University of Birmingham, 
UK. Each slide contained in duplicate 53 different Echinococcus peptides plus 
a spotting control (TAMRA-labeled unrelated peptide), and human IgG as a 
control for the performance of the conjugate. Duplicates were arranged in two 
blocks. Signals were analyzed separately for each block. Therefore, per slide 
zero, one or two positive signals could be obtained for each peptide.  
 
The microarray screening was performed as previously described [27]. Briefly, 
the microarray slides were blocked over night in assay buffer (1 x PBS pH 7.4, 
0.05% Tween20, 3% milk powder), incubated for two hours with sera diluted 
1:100 in assay buffer, washed extensively in PBS-T (1 x PBS pH 7.4, 0.05% 
Tween20) and incubated for one hour with a 1:100 dilution of Cy5-labeled 
goat anti-human IgG (H+L) conjugate (Jackson ImmunoResearch 
Laboratories product number 109-175-088) diluted in assay buffer. Slides 
were washed extensively in PBS-T first, then PBS and before drying with 
compressed air quickly rinsed with deionized water.  
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64 microarrays were incubated with following sera: 8 blood donor sera, 1 pool 
made of 5 AE sera, 20 single AE sera, 10 CE sera, 3 sera from other cestode 
infections (2 Taenia solium, 1 T. saginata), 13 sera from nematode infections 
(1 Trichinella spiralis, 1 Trichuris trichura, 2 Ascaris spec., 1 hookworm, 1 
Mansonella perstans, 1 Loa loa, 1 Onchocerca volvulus, 1 Strongyloides 
stercoralis, 2 Toxocara canis), 6 from trematode infections (2 Schistosoma 
mansoni, 2 S. haematobium, 4 Fasciola hepatica) and 3 sera from patients 
with amoebic liver abscess.  
 
The dried slides were scanned at 532 and 635 nm using a GenePix 4100A 
microarray scanner (Bucher Biotec AG, Basel, Switzerland). Cy5 and TAMRA 
images and local background corrected fluorescence intensities (FI) were 
acquired using the Axon GenePix Pro 6.0 software. Further analysis was done 
in Microsoft Excel. The cut-off fluorescence intensity (FI) was calculated for 
every peptide feature separately as average blood donor FI plus three times 
the standard deviation. 
 
ELISA 
ELISAs were done in 96-well plates (NUNC Immobilizer Streptavidin) as 
described elsewhere [27] with the following modifications: initially all peptide 
candidates were coated at a concentration of 4ug/ml. For the best performing 
peptide (MA2_H3) the optimal coating concentration was determined by 
peptide titration to be 0.025ug/ml.  
 
The absorbance was measured at 405nm (A405) in a VERSAmax microplate 
reader. The raw data was transferred into Microsoft Excel and blank 
corrected. The cut-off value was calculated as average blood donor A405 value 
plus 2 standard deviations from the results obtained from 52 healthy blood 
donors.  
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The sensitivity (true positives / true positives + false negatives) was calculated 
for AE and CE sera separately. Test blood donor samples (n=35) different 
from those used for cut-off calculation together with the samples from 
helminthic infections other than echinococcosis (n=64) served for calculation 
of specificity (true negatives / true negatives + false positives).  
 
Results 
Most translations of EST reads produced similar results by both algorithms 
with one obvious difference being the unequal length of protein sequences. 
FrameDP tended to shorten the protein sequences N-terminally to produce 
methionine at the starts. In addition, FrameDP corrected for frameshifts 
leading to extensions at the C-terminus when compared to the corresponding 
Perl-translated sequences. Considering the different capacities of these 
translation algorithms, we decided to combine the outputs. Thus, the 2 E. 
multilocularis and the 5 E. granulosus EST libraries containing a total of 
23’684 EST reads produced 38’289 theoretical protein sequences by both 
translation algorithms together. To check the quality of these translations, our 
database was searched by blastp for the presence of 6 known Echinococcus 
antigens. All but one protein were detected.  
 
All 38’289 theoretical protein sequences were subjected to alpha-helical 
coiled-coil prediction by Paircoil2. 626 protein sequences were predicted to 
contain one or more CC domains. Redundant sequences were removed 
leading to a final data set of 158 sequences (table 1). The corresponding 
translated EST reads were further analyzed by StableCoil. The Paircoil2 and 
StableCoil algorithms agreed in the prediction of CC domains in 127/158 
sequences. From these regions of overlapping Paircoil2 and StableCoil 
predictions, 53 peptides were selected (table 2). The respective parent EST 
sequences were blasted against the translated protein database in order to 
identify reads with similar sequences. This made it possible to assess the 
species specificity of these peptide sequences. 18 peptides were specific for 
E. multilocularis, 25 were specific for E. granulosus, 5 were identical in both 
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species and 3 showed a difference of 2, 3 or 4 amino acids between the two 
species (table 2).  
 
Due to the limited availability of patient’s sera, the screening of the peptide 
candidates was performed by microarray. This technique uses only 2ul of sera 
for parallel screening of 53 different peptides. Fluorescence intensities from 
the microarray experiments were translated into a one digit value and the sum 
of positive signals is shown in table 3. Peptides MA2_F4 and MA2_F12 and 
MA2_H3, the three peptides most reactive with sera from echinococcosis 
patients (see peptide score 1 in table 3), were found to be also most cross-
reactive with sera from infections other than echinococcosis (see peptide 
score 2 in table 3). 18/53 peptides yielded ≥1 positive signals in microarray. 
These 18 peptides were transferred into the 96-well ELISA format to further 
evaluate the potential diagnostic reagents in the format currently used in 
routine diagnostics.  
 
In ELISA, the peptide candidates were first assessed with sera from 3 AE and 
3 CE infections as well as 1 blood donor sample. 7 out of 18 peptides were 
reactive with one or more of these echinococcosis sera and hence were 
further tested with an extended serum panel of additional echinococcosis 
patients, additional blood donors and patients with other parasite infections.  
 
Peptides MA2_F4 and MA2_F12 which were among the peptides with the 
highest reactivity in microarray assays with peptide score-1 of 9 and 5, 
respectively (table 3), repeatedly gave no signal in ELISA. Peptide MA2_F2 
(peptide score-1 = 5) was excluded because of low sensitivity in ELISA. 
Peptides MA2_H3 (peptide score-1 = 5) and MA2_E8 (peptide score-1 = 4) 
and MA2_E10 showed promising results with echinococcosis sera. Peptides 
MA2_E8 and MA2_E10 disqualified due to high cross-reactivity with both, 
blood donor sera and sera from infections other than echinococcosis. Peptide 
MA2_H3 emerged as best candidate and was subsequently tested with a 
large serum panel.  
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A cut-off of A405 = 0.100 was determined for MA2_H3. This peptide proved to 
be reactive exclusively with sera from AE patients (table 4). 12/42 AE samples 
were tested positive resulting in a sensitivity of 29%. Limited cross-reactivity 
was observed with 1/10 neurocysticercosis sera and 1/9 fasciolosis sera and 
2/35 blood donor sera (table 4) leading to a specificity of 96%.  
 
Discussion 
The literature holds records of synthetic peptides of good diagnostic value 
showing the same or even higher sensitivity than the respective native parent 
proteins [10,13], but reports also about reduced sensitivity [29,30]. Reduced 
sensitivity of peptides is likely due to a much shorter length compared to 
recombinant proteins or native antigen extracts and therefore potentially less 
epitopes. This hypothesis about antigen-length was supported by our previous 
work where a single 42mer E. multilocularis synthetic peptide had shown a 
rather high sensitivity of 57% in a comparable evaluation procedure [27]. This 
peptide derived from antigen B8/1 (accession number BAC77657). Native 
antigen B8/1 comprises 65 amino acids in length (without signal peptide) and 
thus represents a comparatively small protein. An advantageous coincidence, 
since this diagnostically well-proven major component of hydatid cyst fluid 
might be produced entirely by chemical synthesis.   
 
Another explanation of decreased sensitivity of synthetic peptides was loss of 
conformational epitopes [30]. Using synthetic peptides in ELISA, adequate 
coating of such short antigens was recognized as key factor in test 
reproducibility. In the present work, we circumvented this problem by using a 
biotin-streptavidin system for peptide immobilization. Peptides were 
synthesized with an N-terminal biotin separated from the peptide by a PEG-
spacer, thus providing full flexibility and preserving the entire peptide 
sequence for unrestricted antibody binding. Coating the peptide antigens to 
streptavidin ELISA plates prevented epitope masking or destruction caused by 
passive adsorption of the peptides to the polystyrene surface of conventional 
ELISA plates. Instead immobilization via biotin-streptavidin enabled a 
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directional and highly dense coating (every streptavidin has four biotin binding 
sites), resulting in reproducible test results.   
 
The diagnostic value of peptide antigens also depends on their ability to mimic 
native epitopes. We aimed at the selection of 30mer peptides that are 
predicted to adopt a secondary structure that remains stable and reproducible 
under test conditions and in addition reflect the native conformation. The 
alpha-helical coiled-coil motif meets both of these requirements.  
 
From a total of 23’684 redundant EST reads, 158 non-redundant sequences 
had one or more predicted alpha-helical coiled-coil domains. 53 peptides from 
stretches of predicted alpha-helical coiled-coils were selected for screening on 
a microarray platform for reactivity with patients’ sera. Validation by ELISA, 
the assay format currently used in routine diagnostics, followed on the 18 
peptides identified by microarray screening. 8/18 peptides were also reactive 
with echinococcosis sera in ELISA. Further validation with extended panels of 
sera revealed either low sensitivity with echinococcosis sera and/or high 
crossreactivity with sera from other helminthic infections, for example peptide 
MA2_E8 which derived from EST read EGPSPsl-5d04.p1k with similarity to 
the Schistosoma mansoni circulating cathodic antigen (CAA; accession 
number O02197). This peptide obtained promising results with echinococcosis 
sera, but had to be dismissed because of strong cross-reactivity not only with 
Schistosoma mansoni, S. haematobium and S. mekongi, but also with 
Fasciola hepatica and several different nematode infections. Monoclonal 
antibodies against CAA are used in urinary dip stick tests for the detection of 
schistosomiasis [31]. This test was shown to be of limited use for the detection 
of S. haematobium infection [32]. While in our tests the observed cross-
reactivity made peptide MA2_E8 unsuitable for echinococcosis diagnostics, it 
nonetheless hints at the possibility to improve the dip stick assay for detection 
of S. haematobium infection.  
 
The most promising peptide was MA2_H3 that corresponds to EST-read 
EGPSgr-14a07.p1k from an oligo-capped cDNA library of the protoscolex 
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stage of E. granulosus (Wellcome Trust Sanger Centre). In order to identify 
orthologs in both Echinococcus species, a blastp search was performed in all 
translated ESTs. No other match besides the original EST read EGPSgr-
14a07.p1k was obtained. This suggested that the hypothetical protein 
identified likely is E. granulosus specific. But in contrast to this expectation, 
our immunologic screening indicated that peptide MA2_H3 was reactive only 
with AE sera (E. multilocularis). 12/42 AE patients tested positive, while none 
of the 32 CE sera were positive in MA2_H3-ELISA. MA2_H3 had a sensitivity 
of 29% for AE infection. The panel of echinococcosis sera needs to be 
increased to elucidate this issue further and to confirm the observed E. 
multilocularis specific reactivity of MA2_H3. 
 
Specificity for only one Echinococcus species was previously observed for 
antigen EmII/3, a protein transcribed and translated in both, E. multilocularis 
and E. granulosus [33,34]. EmII/3 was shown to localize to the 
undifferentiated germinal layer of the E. multilocularis metacestode tissue [35]. 
The orthologs have 98.6 % sequence similarity at amino acid level. But only 
about 6% of CE patients have antibodies against recombinant EmII/3-10, a 
fragment of EmII/3 [36]. Differing cyst biology of the well-delineated and 
encapsulated E. granulosus cyst as opposed to the infiltrative growing E. 
multilocularis metacestode, where parasite cells probably are in direct contact 
to host cells, was a suggested reason for the differential recognition of EmII/3-
10 [33]. However, recombinant EmII/3-10 has been successfully used for 
differential diagnosis of E. multilocularis infection [37]. 
 
Specificity of MA2_H3 determined to be 96% based on extensive testing with 
control sera. Very few false positive results were obtained, i.e. in 1/10 patients 
infected with Taenia solium, 1/9 patients infected with Fasciola hepatica and 
2/35 blood donors. 
 
Despite the fact that no homologue of read EGPSgr-14a07.p1k was found in 
both E. multilocularis EST-libraries, a tblastn search at http://www. 
sanger.ac.uk/cgi-bin/blast/submitblast/Echinococcus against the E. 
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multilocularis contigs from shotgun sequencing returned a scaffold which 
contained our peptide sequence. In lack of any annotated Echinococcus 
genome data, we carried out gene prediction with GeneMark [38] using the 
prediction model for Caenorhabditis elegans (data not shown). An ORF with 
two predicted exons was retrieved. The full-length predicted protein comprised 
137 amino acids. GPI-som [39] predicted a C-terminal signal peptide, but no 
GPI-anchor site. No transmembrane domain was found (TMHMM [40]). 
PSORT II [41] predicted the protein to be most likely cytosolic. A blastp search 
at NCBI did neither find any conserved domains nor any significant similarity 
to any database entry (data not shown). The finding that this unknown protein 
seems to have no homology and is potentially even unique to Echinococcus 
spp., argues for further evaluation as diagnostic antigen. From such an 
antigen, fewer false positive results might be expected than from well 
conserved protein domains. 
 
In conclusion, peptide MA2_H3, with a sensitivity of 29% and a specificity of 
96%, has great potential to become a further component of a multiplexed 
diagnostic test for echinococcosis diagnosis. We envisage a test platform that 
can accommodate a panel of independent synthetic antigens, either targeting 
echinococcosis alone or in combination with other helminthic infections. New 
technologies, such as the Luminex microsphere based multiplexing system 
provide new options for parallel measurements. Synthetic peptides are ideal 
reagents for these perspectives, as their termini can be modified easily to 
facilitate coating of beads or microarrays. We anticipate an increase in 
sensitivity and specificity in multiplexed testing. In particular gains in sensitivity 
are likely as individual cut-offs for each peptide could be maintained. It is also 
conceivable that a greater number of peptides could be combined to allow 
diagnosis of several infectious agents in parallel in a single assay.  
 
It is likely that using the here described methods for peptide identification 
could lead to a sensitive and specific serodiagnosis independent of native 
parasite extracts. 
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Table 4: 
Numbers of positive ELISA results obtained by peptide MA2_H3 
 
  H3 
Cut-off   0.100 
   
Healthy total n positive n 
Blood donors (cut-off) 52 3 
Blood donors (test) 35 2 
   
Cestode infection     
Echinococcus multilocularis 42 12 
Echinococcus granulosus 32 0 
Taenia solium 10 1 
   
Nematode infection     
Trichinella spiralis 2 0 
Toxocara canis 10 0 
Anisakis spec. 1 0 
Hookworm 1 0 
Strongyloides stercoralis 7 0 
Loa loa 4 0 
Mansonella perstans 1 0 
Onchocerca volvulus 2 0 
Ascaris spec. 6 0 
   
Trematode infection     
Paragonymus westermani 1 0 
Fasciola hepatica 9 1 
Schistosoma mansoni 7 0 
Schistosoma haematobium 2 0 
Schistosoma mekongi 1 0 
   
Amoeba infection     
Entamoeba histolytica 10 0 
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Abstract 
The performance of a synthetic peptide as marker for serological follow-up of 
young cystic echinococcosis (CE) patients was explored by ELISA. From 40 
young CE patients (3 to 14 years) from Tunisia, 226 consecutive serum 
samples were collected at the time point of diagnosis and in regular intervals 
after initiation of treatment (surgery and/or chemotherapy with albendazole). 
The patients were followed over 5 years. Based on clinical findings and 
supported by imaging methods, patients were retrospectively grouped into 
cured (CCE, n = 31) and non-cured (NCCE, n = 9) cases. All serum samples 
were comparatively tested with synthetic peptide EmLD89 ELISA versus 
EgHF-ELISA. In cured patients, 24/31 sera were reactive with peptide 
EmLD89 at diagnosis, compared to 30 positives with the EgHF-ELISA. All of 
these 24 patients showed a gradual decrease in antibody levels. 3 years after 
surgery and/or start of chemotherapy 12 (50%) CCE patients became sero-
negative, compared to 5 seronegatives by EgHF-ELISA. All but one NCCE 
patients exhibited constantly high antibody titers against peptide EmLD89. 
This study provides proof-of-principle that synthetic peptides are suitable 
markers for the serological follow-up of CE patients. 
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Introduction 
Cystic echinococcosis (CE) in humans is caused by the development of 
metacestode larvae of the taeniid tapeworm Echinococcus granulosus in the 
liver, lung, or any other organ. Up to 80% of patients suffer from infections of a 
single organ and present one solitary cyst [1]. Humans are accidental 
intermediate hosts and usually represent a dead end in the development of 
this parasite, since the life cycle of E. granulosus relies on infected 
intermediate hosts (herbivores such as e.g. voles) to be eaten by carnivorous 
final hosts, e.g. dogs. Intermediate hosts acquire infection by ingestion of 
eggs, released by adult tapeworms living in the small intestine of definitive 
hosts via faeces. Echinococcus eggs are highly resistant, and may remain 
infective for about one year in a suitable, moist environment at lower 
temperatures [2]. Sources of infection to humans may be the handling of 
infested definitive hosts (eggs have been shown to stick to the coat of dogs) 
or egg-contaminated soil as well as eating of contaminated vegetables, salads 
and fruits [2]. Cystic echinococcosis is a cosmopolitan zoonosis closely linked 
to animal husbandry, thus the highest prevalence rates among humans and 
animals occur where livestock production is extensive and where dogs have 
access to offal after uncontrolled slaughter [3].  
 
The initial phase of infection is always asymptomatic and many, especially 
small cysts (<5cm) may remain without causing symptoms for years or even 
permanently (up to 60% of the cases) [1]. CE may become symptomatic if 
growing cysts start to exert pressure on adjacent tissue [1]. The diagnosis of 
E. granulosus infection is based on case history, clinical findings, lesions 
identified by imaging techniques such as ultrasound (US), computed 
tomography (CT) or magnetic resonance imaging (MRI) and serological 
means [4]. In fact, without confirmation by immunological tests, the diagnosis 
based on imaging methods remains doubtful for certain cysts, which can 
hardly be distinguished from other cyst-like “space occupying lesions” [5].  
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Over the years, a wide range of immunodiagnostic techniques have been 
applied and less adequate methods such as the complement fixation test 
have been replaced. Now commonly used in routine laboratory testing are the 
ELISA (enzyme-linked-immunosorbent assay), the IHA (indirect hem 
agglutination the IFAT (indirect fluorescence antibody test) and IB 
(immunoblotting).  
 
The treatment of human CE consists of three options: surgery, PAIR 
(puncture, aspiration, injection, re-aspiration: percutaneous puncture of the 
cyst guided by ultrasound imaging, followed by aspiration of some cyst fluid 
and injection of a parasitocidal solution and finally reaspiration) and 
chemotherapy with benzimidazoles [6]. If the clinical condition of the patient 
and the location and type of cyst allow PAIR, this would be the treatment of 
choice. Removing the parasite by PAIR or surgery can lead to complete cure. 
However, the main complication is relapse due to incomplete removal or 
spillage of parasite material during surgery, leading to the formation of new 
cysts (secondary echinococcosis). Careful follow-up of echinococcosis 
patients after surgery is indicated for several years after treatment. Initial 
check-ups should be scheduled every 3-6 months and later on once per year 
[7]. Thus an appropriate strategy for reliable evaluation of treatment outcome 
is compulsory, leading to quick detection of recurring or newly growing cysts. 
The use of US and CT scans for follow-up of hydatid patients has become 
essential [8], but imaging techniques sometimes fail to show small changes or 
differences between viable, dying-out and even calcifying cysts. 
Immunodiagnostic tests are therefore highly appreciated tools to complement 
imaging procedures in the monitoring of treatment outcome, provided they 
yield the expected prognostic performance.  
 
The major source of antigen applied in tests for both, primary as well as 
follow-up diagnosis, is E. granulosus hydatid cyst fluid [9-11]. Native antigen 
such as cyst fluid is extracted from various sources and is non-standardized in 
terms of quality and contents. To overcome limitations associated with native 
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antigen, different recombinant antigens for diagnosing primary and/or follow-
up CE were used. Among these were recombinant B2t [11] and recP29 [12].  
 
A consequent further development would consist in the design of synthetic 
antigens generated by chemical synthesis. Custom-made and commercial 
synthesis is widely available. Synthetic peptides can be routinely produced up 
to a length of 30-50 amino acid residues using a multi-channel peptide 
synthesizer or even up to 100-150 amino acids using a single-channel 
synthesizer [13]. Our previous work and that of others have demonstrated that 
synthetic peptides are well recognized by natively induced antibodies [14,15], 
probably by mimicking immunodominant epitopes. Previously we identified a 
42mer synthetic peptide with a sensitivity of 74% for adult CE cases, which 
also strongly cross-reacted with alveolar echinococcosis patients infected with 
the closely related E. multilocularis [14]. Hence the peptide EmLD89 was 
considered as potential marker for serological follow-up of CE patients. We 
compared the peptide’s diagnostic performance to results obtained by crude 
hydatid cyst fluid and to ELISA results obtained by using recombinant P29. 
The latter results were published previously [12]. To our knowledge, this is the 
first study to investigate the performance of a synthetic peptide for the use in 
immunodiagnostic follow-up.  
 
Materials and methods 
Human serum samples 
The sensitivity and specificity of the EmLD89 batch used in this study was 
determined as described previously using an echinococcosis serum panel 
consisting of 33 CE and 43 AE adult Central European patients [14]. 
Echinococcosis in these patients had been diagnosed as described by Müller 
et al. [16]. All patients had active hepatic lesions of either CE1 or CE2 type 
(WHO-IWGE standardized classification). Blood samples were taken prior to 
any therapeutic intervention, i.e. before surgery and/or chemotherapy.  
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The cut-off value for differentiation of positive and negative test results was 
calculated from the A405-values obtained from 50 healthy blood donors living 
in Switzerland (average plus 2 standard deviations). 
 
For testing cross-reactivity, sera from 74 different patients were used. 10 
patients were infected with Taenia solium, 2 with Trichinella spiralis, 10 with 
Toxocara canis, 1 with Anisakis spec., 1 with hookworms, 7 with 
Strongyloides stercoralis, 4 with Loa loa, 1 with Mansonella perstans, 2 with 
Onchocerca volvulus, 6 with Ascaris spec., 1 with Paragonismus westermani, 
7 with Schistosoma mansoni, 2 with S. haematobium, 1 with S. mekongi, 9 
with Fasciola hepatica and 10 with Entamoeba histolytica. Concomitant 
echinococcosis was ruled out by clinical and serological criteria.  
 
The dynamics of the humoral anti-CE response was investigated with 226 
serum samples from 40 young patients, aged between 3 and 14 years, 
diagnosed and treated for CE at the E. P. S. hospital of Monastir, Tunisia. 
These patients had been part of previous studies investigating the serological 
follow up of CCE versus NCCE patients [9,12,17]. Some of the patients 
presented with a relapse at begin of the study, i.e. they had previously been 
diagnosed with CE and treated accordingly, but treatment was not successful. 
Briefly, the study design was as follows: all cases were surgically, 
radiologically and/or histologically proven (table 1). The first serum sample 
(D0) was collected at the time of diagnosis of CE (or relapsing CE), i.e. before 
medical intervention in the course of the study which was either surgery 
and/or chemotherapy with albendazole. Both, regular blood samples were 
taken and radiological examinations were performed after 7 days (D7), 1 
month (1M), 6 months (6M) and once at a later stage up to 5 years after 
surgery and/or chemotherapy (1Y - 5Y). The intervals and time points of 
sampling varied between the patients. The number of serum samples per 
patient ranged from 4 to 7. Hydatid cysts were classified into 5 categories 
according to WHO criteria [18]. At the endpoint of the follow-up period of 5 
years, the patients were clustered into 2 groups according to the types of cyst 
present: group A consisted of cured or inactive hydatid disease cases. The 
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cysts had successfully been removed by surgery, had completely calcified 
(cyst type CE5) or remained inactive during the whole period of follow-up. 
Patients of group B presented with hydatid disease still ongoing (cyst type 
CE1, CE2 and CE3), either because surgery had not been feasible or had 
been incomplete.  
Peptide  
Peptide EmLD89 (biotin-PEG-KMLGEMKYFFERDPLGQKLVDLLKELEEVFQ 
MLRKKLRTALK) was custom made by Alta Bioscience, Birmingham, UK. The 
peptide was synthesized with C-terminal amide modification. “Crude” 
synthesis was chosen as purity level, because only full-length peptides were 
supposed to contain biotin and thus be able to bind to streptavidin coated 
ELISA plates. The shortfall of crude synthesis is an unknown amount of full-
length peptide, thus making it necessary to determine optimal coating 
concentration for every newly synthesized batch of peptide. The peptide 
concentrations given here assume a consistent yield of 1mg of full-length 
peptide per synthesis reaction. According to the manufacturer’s 
recommendations, the lyophilized peptide EmLD89 was dissolved in 25% 
DMSO in dH2O to produce stock solutions of a concentration of 4mg/ml.  
 
ELISA 
The optimal coating concentration for peptide EmLD89 of 0.25ug/ml was 
determined by peptide titration. ELISA was performed in 96 well plates (NUNC 
immobilizer streptavidin, Denmark). Coating was done in 1x PBS pH 7.4 
(Sigma product number P4417). Plates were washed twice with PBS pH 7.4, 
0.05% Tween20 and then coated over night at 4°C with 100ul/well of peptide 
dilution. All following steps were carried out at room temperature. The plates 
were washed twice and blocked for one hour with 150ul/well of assay buffer 
(3% milk in PBS pH 7.4, 0.05% Tween20, 0.5mM biotin). After three washes, 
the plates were incubated for one hour with human sera diluted 1:200 in assay 
buffer. Plates were washed again three times and incubated for one hour with 
100l/well of conjugate diluted 1:1000 in assay buffer (anti-human IgG 
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alkaline-phosphatase, Sigma product number A 3187) followed by three 
washes. Wells were then incubated for 10 minutes with 100ul of p-nitrophenyl 
phosphate (Sigma product number N 4645) at a concentration of 1 mg ml-1 in 
substrate buffer (13.2 mM Na2CO3, 35 mM NaHCO3, 1mM MgCl2x6H2O, pH 
9.6). Absorbance values (A405) were measured at 405nm in a VERSAmax 
microplate reader.  
 
All serum samples from a given follow-up patient were tested on the same 
plate in order to avoid inter-plate test variation. All samples were tested in 
duplicates. The two values were averaged and blank-corrected. 
 
Data analysis 
Raw data from the microplate reader was processed in Microsoft Excel. 
Average and standard deviation were calculated in Excel. Graphs were 
created using GraphPad Prism version 5.03 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.com.  
 
EgHF-ELISA and recP29-ELISA data from the same patients were retrieved 
from previous studies documented earlier [9,12,17]. 
 
Results 
Operating characteristics of peptide EmLD89 
The operating characteristics of a newly synthesized batch of EmLD89 were 
highly similar to those of batch1 EmLD89 assessed in a previous study [14]. 
The cut-off value of the previous batch EmLD89 was A405 = 0.165, that of the 
current one was A405 = 0.166. The current EmLD89 showed a comparable 
and slightly higher sensitivity for the detection of CE infection in adult patients 
of 75% compared to 72% of the previous batch EmLD89.  
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Performance of peptide EmLD89 ELISA in patient follow-up  
226 serum samples from 40 patients (31 CCE and 9 NCCE) collected at 9 
different time points were tested with EmLD89. These samples had been 
tested previously in EgHF ELISA and Western blot and recP29 ELISA and 
Western blot [9,12,17]. A comparison of our EmLD89 results with these 
antigens is shown in table 2 for both, CCE and NCCE samples.  
 
Baseline samples (D0) were available from 34 patients (27 CCE, 7 NCCE). 18 
of these D0 serum samples tested positive in peptide EmLD89 ELISA 
resulting in a sensitivity of 53% for the detection of CE infection in children 
and adolescents. D0 sensitivities in these young patients for EgHF- and 
recP29-ELISA were 77% and 21%, respectively.  
 
The development of antibody levels of CCE (31 patients) and NCCE (9 
patients) in response to peptide EmLD89 is shown in figures 2 and 3, 
respectively. In general, the antibody levels increased after surgery/treatment 
and peaked at time point 1M followed by a decrease of antibody level visible 
in the CCE cases (figure 1), while the NCCE cases showed high antibody 
levels at all times, also at the end of the individual follow-ups (A405 1.113 - 
3.879) (figure 2). The peak of anti-Echinococcus antibodies 1 month after 
surgery/chemotherapy was also seen in EgHF- and recP29-ELISA.  
 
24/31 CCE patients were positive for peptide EmLD89 at one or several time 
points tested. Among these 24 patients, 15 presented with liver cysts, 8 with 
lung cysts and 1 with multiple cysts in liver and peritonea. From 20 of these 24 
patients, a D0 sample was available. 8/20 were EmLD89 negative at D0 (5 
lung cases and 3 liver cases) but seroconverted during treatment. The 
dynamics of antibody recognition of the 24 EmLD89 positive CCE patients 
were as follows: 10/24 reached antibody titers below the cut-off within 3 years 
after surgery/chemotherapy (figure 3). One of these was only responding 
weakly to EmLD89. 10/24 CCE patients showed considerable decrease in 
anti-EmLD89 antibody levels. At the end of the follow-up period, 7 of these 
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were still clearly above cut-off while the remaining 3 patients reached A405 
values only slightly above cut-off (A405 = 0.177, 0.192 and 0.172; cut-off = 
0.166). 2/24 EmLD89 positive patients showed no major change in antibody 
levels, but the patients were monitored only for one and two years, 
respectively. Their corresponding EgHF A405-values were also high at all time 
points. The remaining 2/24 CCE patients showed patterns not resembling any 
of the others: both were EmLD89 positive only at one time point during the 
entire follow up period, namely at 1M and 6M, respectively. 1 CCE patient was 
positive at D0 and 6M, all other samples from this patient were EmLD89 
negative. The corresponding EgHF-ELISAs were highly positive at all time 
points.  
 
7 CCE patients showed no reactivity at all with peptide EmLD89 throughout 
the entire period of follow-up (6 lung cases, 1 with multiple cysts in lung and 
peritonea). One of these 7 patients, patient no. 34, with a lung cyst, showed 
no reactivity with any antigen in any test applied at any time point tested. The 
remaining 6 patients were positive at one or more time points tested in EgHF-
ELISA and 1 patient was additionally positive in recP29 ELISA.  
 
Regarding the 9 NCCE patients, 8/9 showed high antibody levels at the first 
time point tested (DO, D7, 1M, respectively; A405 > 1.5). 1 NCCE patient 
remained negative until 2 years after surgery, but had been positive in EgHF 
ELISA from D7 onwards.  
 
Discussion 
Recurrence of cysts is frequently observed in human echinococcosis. A 
number of reports indicated that about 25% of all CE cases showed relapse 
following treatment by either surgery or chemotherapy [4,5,19,20]. Despite 
intensive research, no specific test for monitoring follow-up patients has been 
developed yet. Current routine diagnostic tests use the same antigens as for 
the detection of primary echinococcosis. These antigens generally derive from 
100
CHAPTER 4 
 
crude or partially purified hydatid cyst extracts. Improved immunodiagnostic 
tools for treatment monitoring are still in need today.  
 
The present work assessed the potential usefulness of a synthetic peptide for 
serological follow-up of CE patients. Peptide EmLD89 had previously been 
identified by screening on a microarray platform 45 different peptides 
originating mostly from known antigens and by combining two highly reactive, 
overlapping peptides (29mer and 27mer) in one long synthetic peptide 
(42mer) [14]. EmLD89 corresponding to antigen B8/1 of E. multilocularis 
(accession number BAC77657) reacted well with sera from both, adult AE 
(43% sensitivity) and CE cases (74% sensitivity) [14].  
 
Differences in antibody levels have been attributed to cyst location and/or the 
number of cysts. Multiple cyst infestation was shown to lead to slower 
antibody decrease after successful treatment [17]. Cysts in the brain or eye 
and calcified cysts often induce low or no antibody response [1]. Hepatic cysts 
are thought to elicit higher antibody levels than pulmonary cysts [21,22]. We 
found that peptide EmLD89 did not differ in reactivity for sera from liver 
compared to lung cases. In contrast, 6 of the 7 CCE cases, all non-reactive 
with EmLD89, had pulmonary cysts. This confirmed previous reports that 
pulmonary cysts were weakly or not recognized by the host immune system 
[17].  
 
The sera tested in this study were collected from young CE patients from 3 to 
14 years of age [9,12,17]. CE may reach medical attention in all age groups 
with peaking numbers of cases in 6 to 15 years-old [1]. Diagnosis in children 
and adolescents is difficult, because their antibody response may be low [1]. 
Indeed, a lower response was observed also in our study participants. From 
our 40 patients 34 D0-samples were available, 18 of which were EmLD89-
positive. This resulted in a sensitivity of 53% in young patients and compared 
to a sensitivity in adults of 74%. 
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From 31 CCE patients, 24 were positive with peptide EmLD89. All NCCE 
patients were positive for EmLD89. One NCCE patient tested positive only 2 
years after treatment. In fact, this patient had a relapse two years after initial 
surgery. This patient can be considered non-responsive to peptide EmLD89 
during the initial infection, whereas the delayed response was caused by the 
relapse giving rise to an anti-EmLD89 antibody development. The serological 
profile of this patient tested in standard EgHF-ELISA was considered normal. 
However, it showed negativity at baseline sampling, but followed by 
seroconversion after the first surgery. This patient therefore highlights the 
need for increasing the sensitivity of peptide-based testing. Increased 
sensitivity might be obtained by complementing EmLD89 with peptides that 
represent epitopes different from antigen B1 epitopes.  
 
The major difference between the CCE and NCCE group was the gradual 
decline in antibody levels among the CCE patients measured by A405-values. 
All but one NCCE case showed constantly high antibody levels even at the 
end of follow-up (5 years). The trend in antibody-level decrease measured in 
EmLD89-ELISA corresponded well to that seen in ELISA using native cyst 
hydatid fluid, but in EmLD89-ELISA more patients became sero-negative 
within 3 years after treatment compared to outcomes measured by native cyst 
fluid ELISA (12 patients versus 5 patients in our study population). This 
reflects a better resolution of antibody decline with peptide EmLD89, a single 
representative from the antigen B multi-gene-family, as compared to native 
cyst fluid containing a mixture of several antigen B subunits from different 
antigen B family members. 
 
Recently, it was shown that the antigen B family comprises at least 10 genes 
and that all of them are conserved in parasites from different hosts and 
different geographical locations [23]. In addition, differential expression of 
antigen B family members in larval and adult developmental stages was found 
[23]. Antigen B3/1 was the predominant subunit expressed throughout the life 
cycle in all developmental stages investigated [23].  
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This recently published information on conservation and expression of antigen 
B highlights the suitability of this antigen for diagnostic purposes. In our 
previous study, we tested peptides from antigen B1 and antigen B2 [14]. 
Peptides corresponding to antigen B sequences were found to be superior in 
reactivity with patients’ sera compared to peptides corresponding to any other 
sequence. Furthermore, we found that antigen B1 peptides showed higher 
sensitivities than antigen B2 peptides (data not shown). Regarding the 
diagnostic operating characteristics of different antigen B subunits, several 
authors reported opposing results. Our data support the findings of Lorenzo et 
al. and González-Sapienza et al., who reported recombinant and peptide 
antigen B1 superior to antigen B2 [24,25]. In contrast, the results of Rott et al., 
Virginio et al. and Hernández-González et al. made antigen B2 the better 
performing subunit [11,26,27]. Slight sequence variations and inclusion or 
exclusion of signal peptide sequences in the recombinant proteins were 
suggested reasons for the differing results [11]. B2t, the recombinant antigen 
B2 subunit, was proposed to perform better because of the missing signal 
sequence and hence representing the mature form of the protein [11]. 
However, EmLD89 does neither contain the signal peptide sequence and 
therefore revives the discussion about the reasons of the observed 
differences. We hypothesize that the discrepancy might be due to technical 
reasons such as different assay protocols leading for example to variable 
coating efficiencies of the different antigen B subunits. In addition, the serum 
panels used for evaluation were different between the studies, raising the 
question how the sensitivities might look like if the serum panels were 
exchanged between the opposing working groups. 
 
In the present work, we have provided proof-of-principle for the value of a 
synthetic peptide as serological marker and strongly suggest the further 
investigation of more synthetic peptides from the whole spectrum of available 
antigen B sequences, especially of antigen B3/1. Consistent with reports from 
other diagnostic peptide studies [28,29], we expect the combination of several 
peptides to increase test sensitivity substantially. Peptide EmLD89 might 
represent the first step in the development of a highly sensitive and specific 
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synthetic antigen pool, resolving the limitations associated with native antigen 
extracts.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  
Time course of antibody levels in CE patients (n=31) tested by EmLD89-
ELISA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: 
Time course of antibody levels in NCCE (n=9) patients tested by EmLD89-
ELISA.  
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Figure 3:  
Time course of antibody levels in CCE patients (n=12) reaching seronegativity 
within 3 years of follow-up. Bars represent mean A405 values. 
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General discussion 
This PhD thesis provides proof-of-principle for the applicability of synthetic 
peptides (20-50mer) as antigens in the diagnosis of human echinococcosis 
infection and it depicts three different approaches to tackle identification of the 
immunome of Echinococcus multilocularis and E. granulosus on the level of 
25-45mer peptides.  
 
Throughout the entire work, the peptide selection criteria remained the same. 
By means of bioinformatics, we selected structural motifs which can adopt 
native folding even as fragments of 25-45 amino acids in length and isolated 
from the context of the whole protein. Such motifs were on the one hand 
intrinsically unstructured (IUR) regions of proteins, potentially representing 
linear epitopes, and on the other hand alpha-helical coiled-coils, potentially 
displaying conformation-depending epitopes [1]. To further confine the regions 
for peptide design within the stretches of predicted CC, we used StableCoil [2] 
to find those CC sections with the highest relative stability. Sequences 
containing predicted IUR were further analyzed with BepiPred [3] for the 
prediction of linear B-cell epitopes. Peptides were finally selected from regions 
of highly stable CC or IURs with predicted B-cell epitopes. 
 
Looking at the secondary structure predictions of the 6 peptide candidates 
identified and characterized in the course of this PhD thesis, 4 peptides were 
based on alpha-helices and only 2 peptides corresponded to predicted B-cell 
epitopes. The yield of B-cell epitope prediction might be considered poor, 
given the fact that about equal amounts of CC and IUR peptides have been 
tested. Our results support the general opinion that the current state of B-cell 
epitope prediction is far from ideal and that more research in this area is 
needed [4]. However, with more and more three dimensional structures of 
proteins being determined, attention is shifting from the prediction of linear B-
cell epitopes to the prediction of discontinuous B-cell epitopes [5].  
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In contrast to given peptide selection criteria, we tested three fundamentally 
different approaches for the selection of parent proteins for peptide design. 
 
The genomics approach (chapter 2) based on a genome-wide search for 
proteins potentially located to the host-parasite-interface, because such 
proteins are thought to potentially elicit an immune response. Bioinformatic 
algorithms were used to identify signal peptides (PSORT II [6]), 
transmembrane domains (TMHMM [7]) and GPI-anchor sites (GPI-som [8]). 
At the time of our bioinformatics search (done on October 16, 2007), NCBI 
Entrez Protein Database contained 240 entries of E. multilocularis and 940 
entries of E. granulosus protein sequences, including redundancy. On the one 
hand, these 1’180 proteins were used as input sequences for prediction of 
localization and on the other hand for predictions of CC (Paircoil2 [9]) and IUR 
(IUPred [10]). The overlap of CC and/or IUR-containing sequences with 
predictions of a potentially extracellular or surface location was very small. 
Only 5 E. granulosus and 8 E. multilocularis sequences were identified 
(without redundancy).  
 
Among the proteins predicted to contain stretches of CC and/or IUR only, a 
considerable number of known antigens were found, e.g. antigen II/3 [11], 
EM13 [12], P29 [13], EG19 [14]. We expanded our selection criteria and 
included all sequences containing CC and/or IUR, irrespectively of their 
potential localization. The set of parent proteins selected by our genomics 
approach therefore comprised protein sequences mainly from known 
antigens. Peptides selected from these parent proteins were screened for 
reactivity with patients’ sera on microarray.  
 
Screening on peptide microarrays is a desirable alternative to screening in 
ELISA, because considerably smaller amounts of patients’ sera are needed. 
To screen 96 different peptides on microarray, 2μl of sera are sufficient, while 
the same screening in our ELISA system would necessitate 50μl of serum. 
We found that the availability of well-defined, parasitologically confirmed 
human serum samples for test development and validation was the most 
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limiting factor. Thus, a technique that preserves limited patient material offers 
a substantial advantage.  
 
After screening on microarray reactive peptides were transferred into ELISA 
format, because ELISA has been routinely used in sero-diagnostics. Our 
method of peptide immobilization via biotin/streptavidin proved ideal as it was 
versatile to accommodate both formats. Peptides were attached to either solid 
phase by binding the N-terminal biotin of the peptides to streptavidin coated 
microscope glass slides or ELISA plates.  
 
At the beginning of this project, we also addressed the question of optimal 
peptide length. Selected peptides found reactive with echinococcosis sera on 
microarray were synthesized again as longer versions of the same antigen 
domain (AltaBioscience, UK). Both, the “short” 27-30mers identified by 
microarray and their corresponding “long” 40-47mer counterparts were tested 
in ELISA. This parallel testing revealed that in general, the “longer” peptides 
performed better than the “shorter” ones.  
 
This finding argued for a modified approach to peptide design. Longer 
peptides would be generally desirable, but this was not compatible with low 
cost peptide synthesis. In a genome wide screen synthesis costs represent a 
major investment and must be kept low. The Episcan peptide synthesis 
technology offered by AltaBioscience (University of Birmingham, UK) enables 
simultaneous synthesis of up to 192 different peptides in 1 to 2 mg quantities, 
but limits peptide length to 30 amino acids. However, the advantages of 
screening a batch of several different peptides at the same time 
simultaneously on microarray with as little as 2ul of patient serum outweighed 
the limitation of peptide length.  
 
The peptide candidate performing best in our genomics approach was peptide 
longD8-9. It was developed on the basis of two overlapping peptides both of 
which were found to be reactive on microarray. The extended version peptide 
reached a sensitivity of 74% for the detection of CE infection and 43% for the 
114
GENERAL DISCUSSION 
 
detection of AE infection in adult patients. 74% sensitivity reached by a single 
peptide is a considerable high value. The sensitivities of the second- and 
third-best candidates were much lower. Peptide longD1 detected 6% of CE 
and 25% of AE cases, peptide longD12 9% of CE and 23% of AE cases. But 
all three peptides reached a specificity ranging from 91 to 94% (chapter 2).  
 
Due to the partial complementarity of their reactivity patterns, we decided to 
further characterize combinations of peptides that were applied as synthetic 
antigen pools. We found that by pooling several peptides, the sensitivity was 
indeed increased, but on the cost of specificity. Single peptides thus exhibited 
decreased sensitivity compared to native antigen but always obtained a high 
specificity of at least 90%, whereas a peptide pool reached higher sensitivity 
but decreased specificity compared to its individually tested components.  
 
The possibility of increasing test sensitivity by combining different peptides 
targets the application of synthetic peptides rather to a screening test which 
requires maximal sensitivity than to a confirmatory test with utmost specificity. 
 
Our second strategy applied to screen for antigenic proteins was a proteomics 
approach, which used  tandem mass-spectrometry to identify proteins from  in 
vitro cultivated E. multilocularis vesicle fluid (EmVF, [15]) (chapter 3). We 
focused on a 20-22kDa fraction that has been found to be diagnostically 
informative in immunoblots with patient’s serum.  
 
A major issue of the proteomics approach was the protein diversity in the 20-
22kDa fraction. The standard search of peptide spectra against the Uniprot 
database identified 11 different proteins. 23 more proteins were identified with 
the help of conceptually translated EST libraries (Wellcome Trust Sanger 
Institute). To further down-select parent sequences for peptide design, we 
concentrated on those proteins highly abundant in the sample and hence 
represented by a large number of tryptic fragments. We designed a number of 
peptides corresponding to different EST sequences with similarity to 14-3-3. 
The evaluation of these peptides showed very little reactivity with sera from 
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patients. Only one 14-3-3-like peptide out of 15 was tested in more detail but 
finally had to be dismissed because of too little sensitivity with echinococcosis 
sera. None of the 14-3-3 peptides was considered for diagnostic use.  
 
The low serological reactivity of Echinococcus 14-3-3 peptides might reflect 
the importance of this protein in many basic cellular events crucial for 
multiplication and survival of eukaryotic cells (reviewed e.g. by Siles-Lucas 
[16]). Antibodies directed against 14-3-3 might heavily interfere with parasite 
growth and therefore 14-3-3 proteins in parasites evolved to be little antigenic. 
In fact, the Echinococcus 14-3-3 protein produced promising results as 
vaccine candidate in a mouse model [17].   
 
The two peptides performing best in our proteomics approach to antigen 
discovery were peptide C2 (from cytosolic malate dehydrogenase) and 
peptide B6 (from phosphoglycerate mutase). Peptide C2 reached a sensitivity 
of 15% and a specificity of 90%, while the sensitivity of peptide B6 was 18%, 
and the specificity 91%. These two peptides showed some degree of 
complementarity in their recognition of echinococcosis sera. Therefore C2 and 
B6 were considered candidates for inclusion in a synthetic antigen pool.  
 
Our third strategy for the selection of parent proteins made use of 
conceptually translated EST sequences of E. granulosus and E. multilocularis 
and was therefore considered a transcriptomics approach (chapter 4). At the 
Wellcome Trust Sanger Institute, the sequences of 2 E. multilocularis and 5 E. 
granulosus EST libraries are available for download. The translation of the 
EST reads represented a challenge, because these libraries often constitute a 
collection of “noisy” data. Start/stop codons are often missing, frameshifts 
occur frequently. We decided to combine the outputs of two translation 
algorithms. On the one hand, we used a conservative Perl script translating 
each of the six possible frames followed by selection of the longest one as 
definitive open reading frame and on the other hand, a more advanced 
algorithm able to deal with incomplete sequences and frameshifts (FrameDP 
[18]).  
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This decision to use both outputs was supported by the proteomics approach. 
Certain peptide spectra measured by MS/MS could be matched either to 
translations made by FrameDP or by the Perl script. For example, the 
FrameDP algorithm tended to shorten the N-terminal region of translations to 
make methionine the first amino acid. In our MS/MS analysis, we found a 
peptide spectrum that matched to the protein region located upstream to a 
methionine that was set as start codon by FrameDP. The identification of this 
spectrum would have been lost using the FrameDP translation only, but it 
could be “rescued” by the Perl translation. On the other hand, FrameDP 
corrected properly for frameshifts leading to translations with a longer open 
reading frame than in the corresponding Perl translation which was truncated 
C-terminally due to the stop codon produced by the frameshift. We also found 
an example of a peptide spectrum that matched to a C-terminal region and 
could only be identified by the FrameDP translation.  
 
As mentioned above, EST libraries often consist of incomplete sequences. 
Predictions of subcellular localization and GPI-anchor sites as carried out in 
the genomics approach were not possible, since these algorithms demand 
complete N- and C-termini. Instead, the main focus was on the prediction of 
stable alpha-helical coiled-coils. The CC motif was preferred over the IUR 
motif because it is generally accepted that the majority of epitopes are 
conformation-dependent epitopes [1].  
 
The transcriptomics approach identified one promising peptide, namely 
peptide MA2_H3. This candidate was the first of all candidates tested that 
reacted exclusively with sera from AE patients. There was no cross-reactivity 
seen with sera from CE patients. Peptide MA2_H3 reached a sensitivity of 
29% for the detection of AE infection and a specificity of 96%.  
 
In summary, the three different selection approaches identified 6 peptides that 
were validated with the entire serum panel (AE, CE, other helminthic and 
Entamoeba infections and blood donor samples). The decreasing amount of 
peptides identified by the three different approaches might reflect the 
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decreasing amount of proven antigens contained in the sets of parent proteins 
selected for peptide design. The most promising peptide candidate longD8-9 
emerged from a set of parent proteins based mainly on known antigens.   
 
Despite CC and IURs being wide-spread in genomes of eukaryotes, not every 
protein sequence does contain either one or both of these domains. For the 
genomics and the proteomics approach, these structural selection criteria 
appeared to be too restrictive. For sequences with low probability predictions 
of CC and IUR domains, a different approach might be better suited, for 
example Pepscan epitope mapping (reviewed e.g. by Meloen et al. [19]). This 
method aims at the identification of linear B-cell epitopes by investigating 
highly overlapping peptides covering the entire protein sequence.  
 
In chapter 5, the application of EmLD89, the most promising peptide identified 
in this PhD work, in a serological follow-up of young cystic echinococcosis 
patients is described. (For the purpose of the follow-up study, the peptide 
formerly termed longD8-9 was renamed to EmLD89.) This represents a 
novelty, because to date no synthetic peptide has been tested as marker for 
serological follow-up of CE patients.  
 
The results obtained in EmLD89-ELISA showed a decrease of antibody titers 
comparable to the one seen in EgHF-ELISA. Titers remained high in non-
cured CE patients with both antigens. Successful treatment can thus be 
monitored by decreasing antibody titers. Within 3 years after treatment, more 
cured CE patients reached seronegativity when tested in peptide ELISA 
compared to native EgHF-ELISA. This finding strongly recommends the 
further investigation of more synthetic peptides for application in serological 
follow-up.  
 
Conclusions drawn from this study were i) microarray technology was well-
suited for the screening of multiple peptides minimizing the use of patient 
serum, ii) longer peptides (40-50 amino acids) performed better than shorter 
ones (20-30 amino acids), iii) one single peptide was not sufficiently sensitive, 
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but sensitivity could be increased by combining several peptides and iv) 
peptide antigens also proved valuable tools in serological follow-up of CE 
patients but their application for this purpose needs further research.  
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